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Sickle cell disease (SCD) is a dangerous condition caused by a genetic 
mutation on the human beta-globin gene that contributes to erythrocyte sickling, the 
hallmark of the disease. Chronic intravascular sickling in peripheral organs can 
contribute to systemic inflammation and multiple organ dysfunctions leading to 
further disease progression. Previous metabolomics studies have confirmed that 
elevated sphingosine kinase 1 (SphK1) mediates sphingosine-1-phosphate (S1P) 
production to promote erythrocyte sickling. S1P signals via five S1P receptors 
(S1PR) that regulates several pathophysiological functions. 
In the first chapter of this dissertation, I explored the role of S1PRs in SCD by 
utilizing pharmacologic and genetic tools. To determine the role of S1P-S1PRs 
signaling in SCD, I treated humanized Berkeley sickle mice (Berkeley HbS mice), 
with FTY720, a US Food and Drug Administration (FDA) approved drug. FTY720 
can be phosphorylated by SphK1 thus mimicking S1P to regulate S1PRs signaling. 
Mechanistically, FTY720 can inhibit S1PR signaling in immune cells by the 
internalization of the receptor. Although FTY720 did not improve erythrocyte life 
span or reduce sickling in SCD mice, FTY720 treated SCD mice showed further 
reduction of inflammatory cells in the periphery, reduced mRNA and protein levels of 
viii 
 
pro-inflammatory cytokine interleukin 6 (IL-6), improved multiple tissue, and renal 
function.  
Since IL-6 is elevated in SCD due to systemic inflammation, I showed that IL-
6 expression in the periphery and local tissues contributes to further upregulation of 
S1PR1 in sickle mice. To test the role of IL-6 in SCD, I generated global genetic 
deletion of IL-6 in sickle mice. Sickle mice with IL-6 deficiency had overall improved 
multiple tissue function, which indicates that IL-6 plays a detrimental role in SCD.  To 
further demonstrate this mechanism, I generated mouse BM-derived macrophages 
to test whether S1P-mediate S1PRs activation, I showed that FTY720 and W146, 
S1PR1 specific antagonists, have immunomodulatory functions that results in the 
reduction of S1PR1 and IL-6 mRNA levels. Moreover, I showed that IL-6 induction 
contributes to further upregulation of S1PR1 mediated via a JAK2-dependent 
manner in macrophages.  
 In the second chapter of this dissertation, I discuss findings generated from a 
highly robust, unbiased microarray screen performed in sickle lung. Several 
upregulated gene pathways were identified in sickle lung, which include iron 
homeostatic genes and inflammatory genes. Unexpectantly, I also discovered 
elevated expression of rhythmic genes, which play a role in regulating biological 
clocks in multiple cell types. Amongst the rhythmic genes detected was Period 2 
(Per2), which regulates circadian rhythms that promotes biological clock function. To 
test whether Per2 mRNA and PER2 protein levels were further induced in sickle 
lung, I utilized a genetic tool, Per2 Luciferase (Per2Luc) mice, a bioluminescence reporter 
mouse model to study PER2 circadian expression. I generated Per2Luc mice with 
ix 
 
SCD or WT phenotype by bone marrow transplantation (BMT) studies. With this 
genetic tool, I detected PER2 luciferase oscillations in ex-vivo lung explant cultures. 
Upregulation of PER2 (based on luciferase activity) regulated in a circadian manner 
was detected in SCD lungs compared to WT lungs, which confirms that Per2 
contributes to clock function.  
  Next, I determined whether biological clocks play a role in SCD. To test this, I 
generated WT and SCD phenotypic Per1/Per2 deficient mice by BMT studies. 
Per1/Per2 deficient mice have abnormal biological clock function, which plays a role 
in disease.  Interestingly, I observed further multiple organ dysfunction, systemic, 
and local tissue inflammation in SCD →Per1/Per2 dKO mice compared to 
SCD→WT mice, which demonstrates that the loss of Per1/Per2 in SCD is 
detrimental and contributes to these devastating effects.  
 In the third chapter of my dissertation, I explored the impact of chronic 
hemolysis mediating elevated heme and iron induction in sickle mice. Since elevated 
heme and iron are toxic to the organs and contribute to multiple organ dysfunctions, 
I explored whether Per1/Per2 was involved. As expected, I observed heme and iron 
trafficking to the sickle liver and spleen organs is due to hemolysis-mediated events 
due to sickling. Chronic inflammation due systemic release of heme in the periphery 
can contribute to heme and iron overload in peripheral tissues to promote further 
SCD progression. Interestingly, I observed iron trafficking to the Per1/Per2 deficient 
sickle lung. To determine a possible mechanism, I detected heme oxygenase 1 (HO-
1), an enzyme that metabolizes heme, in peripheral macrophages in the lung and 
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discovered further elevated expression of HO-1 in sickle mice with Per1/Per2 
deficiency.  
 Overall, my work demonstrates the beneficial role of biological clock function 
in sickle mice. My work will be useful for better understanding biological clocks in the 
context of a highly complicated disease. Although there are several molecular 
triggers that can offset biological clocks, my work has further clarified why Per1/Per2 
genes are essential regulators of clock function by promoting protective functions in 
SCD.  
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I. Introduction  
 
1.1. Etiology of Sickle Cell Disease. 
Sickle cell disease (SCD) is the first cellular, molecular and genetic disease 
characterized in history. In 1910, the first case of SCD was described by Dr. James 
B. Herrick who coined the term “sickle-shaped”, which described the morphology of 
erythrocytes isolated from a patient with pulmonary symptoms (1).  In 1945, Linus 
Pauling was the first to hypothesize that SCD was due to abnormalities in 
hemoglobin (2). To demonstrate this, Pauling performed gel electrophoresis to 
separate hemoglobin in erythrocytes isolated from SCD patients compared to 
healthy patients. There were striking differences in electrophoretic motilities  in sickle 
hemoglobin versus normal hemoglobin (3). Dr. Harvey Itano’s research group 
performed electrophoretic and acid–base titration experiments and concluded that 
there were differences in ionizing properties in the sickle hemoglobin compared to 
normal hemoglobin (3). Further analysis was conducted on sickle hemoglobin that 
confirmed an amino acid substitution from glutamine to valine on the sixth position 
on the β-globin chain (β6 Glutamate →Valine) (4). Thus, the first disease with a 
molecular basis was identified.  Since abnormalities exist in β-globin chain, this was 
linked to the discovery of a nucleotide change of the human beta globin (Hbb) gene, 
which is the cause of this autosomal recessive disease (5).  
1.2. Epidemiology of Sickle Cell Disease. 
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In the US, approximately 100,000 people are living with SCD (7). There are 
approximately 300,000 infants born with SCD worldwide each year (9) with the 
average life expectancy of patients with SCD about 66 years (6). The incidence of 
SCD has significantly increased particularly in sub-Saharan Africa, the islands of the 
Caribbean and the US over the past decades thus leading to high health care costs 
that average more than 488 million dollars in the US alone (6). It is predicted that by 
the year 2050, there will be nearly 10 million SCD patients that will be treated for 
their condition (7). Urgent emergency care is required for the majority of SCD 
patients, which further increases the economic cost. Frequent hospitalizations for 
patients with life threatening complications can lead to high morbidity.  The 
pathological and clinical consequences of SCD include end organ damage, 
priapism, chronic pain, infections, acute chest syndrome, and stroke (6). More than 
half of patients living with severe complications of the disease experience early 
mortality (8).  
1.3. Systemic hemolysis, iron overload, and inflammatory pathways underlying SCD 
progression. 
  Sickle erythrocytes adhesion to the endothelium mediates drastic vascular 
changes, which can contribute to reduced organ function. Systemic hemolysis 
releases circulating hemoglobin, which can scavenge nitric oxide (NO) thus resulting 
in endothelial cell dysfunction (9). NO production is essential for anti-inflammation, 
anti-thrombosis, and vasodilation.  Deficiency in NO production is attributed to the 
abundance of free heme released in the circulation. Elevated heme mediates 
induction of endothelial heme oxygenase 1 (HO-1) to breakdown heme to form iron, 
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carbon dioxide, and biliverdin (10). Bilirubin is a further metabolized product of 
biliverdin. Elevated bilirubin due to systemic hemolysis can result in deposition to the 
bile ducts in the liver and gallbladder.  
 Intravascular hemolysis can contribute to elevated heme-bound iron released 
from hemoglobin. The heme degradation pathway is involved in the metabolism of 
heme-bound iron mediated by HO-1.  Further induction of HO-1 contributes to the 
generation of the end products that result from heme degradation.  In SCD, elevated 
HO-1 induction mediates heme degradation. Due to chronic hemolysis elevated iron 
deposition to multiple organs can become toxic, which can interfere with organ 
function.  Since SCD is a condition of oxidative stress, reactive oxygen species 
(ROS) are generated, a dangerous outcome of systemic hemolysis. Due to the 
abundance of ROS, excess iron can react with ROS , which has drastic effects in 
overall organ function (11).  
1.4. Sphingosine-1-phosphate (S1P) signaling mediates sickling and further disease 
progression.   
 In a unbiased high throughput metabolomics screen, our lab discovered that 
elevated levels of circulating metabolites adenosine and sphingosine-1-phosphate 
(S1P) in SCD (12). Our lab discovered that elevated circulating adenosine, a purine 
nucleoside, mediates erythrocyte sickling through adenosine ADORA2B receptor 
activation by contributing to 2,3-diphosphoglycerate (2,3-DPG) induction that 
promotes oxygen release in erythrocytes (13).  Due to elevated systemic adenosine 
in SCD, this signaling pathway contributes to further disease progression. In fact, 
elevated adenosine-mediated ADORA2B receptor activation in erythrocytes induces 
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sphingosine kinase 1 (SphK1)-S1P production to contribute to further sickling (14) 
(Illustration 1). 
S1P is a bioactive lipid generated from sphingomyelin, a class of 
lysophospholipids. Sphingomyelin is metabolized to form ceramide and further 
metabolized to generate sphingosine. Sphingosine is phosphorylated by two 
isoforms of sphingosine kinases (SphKs) known as SphK1 and SphK2.  Differences 
in enzymatic activity have been observed in SphKs, such that SphK1 translocate 
from the cytoplasm to the plasma membrane whereas SphK2 translocate to the 
nucleus.  Although the role of intracellular S1P is not fully understood, elevated 
extracellular S1P can activate five S1P receptors (S1PRs). Amongst these S1PR 
subtypes, S1PR1 is ubiquitously expressed in multiple cell types, including immune 
cells.  Since the discovery of S1PRs, pharmacologic advances have been made to 
target S1PRs.  FTY720 is a US Food and Drug Administration (FDA)- approved drug  
for treating multiple sclerosis and was developed to target and inhibit S1PR1 
signaling by internalization of the S1PR1 for its degradation in the proteasome (15).     
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1.5. The role of elevated immune responses contributing to vascular dysfunction in 
SCD. 
Immune cell types, such as neutrophils, macrophages, and lymphocytes, can 
contribute to the release of inflammatory meditators that promote multiple tissue 
injuries and disease progression. Systemic and sustained inflammation contributes 
to further progression of SCD, which affects nearly every organ system of the body. 
Predictors of mortality in SCD patients can be characterized as elevated circulating 
levels of inflammatory molecules, such as interleukin 6 (IL-6), monocyte 
chemoattractant protein (MCP-1), tumor necrosis factor alpha (TNF-α), endothelin-1 
(ET-1) (16, 17). In sickle mice, danger associated molecular patterns (DAMPs)  such 
as high mobility group box 1 (HMGB1) can also be released from immune cells or 
damaged tissues to trigger activation of toll-like receptor 4 (TLR4) signaling 
pathways in SCD (18).  
Since systemic inflammation-mediated by erythrocyte sickling contributes to 
multiple organ dysfunction, organ specific inflammatory mediators can contribute to 
the progression of SCD. For instance, in the lung, a mixture of inflammatory cell 
types can release a milieu of inflammatory mediators that contribute to severe 
pulmonary complications in SCD. Previous studies have shown increased levels of 
lymphocytes and cytotoxic T cells in bronchoalveolar lavage (BAL) fluid isolated from 
sickle mice (19).  In addition to elevated immune cells, increased levels of 
inflammatory mediators released from immune cells including interleukin 5 (IL-5), 
granulocyte colony stimulating factor (GCSF), and C-X-C chemokine motif 1 (CXCl1) 
were observed (20).   
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1.6. Utilizing a unbiased microarray screen to investigate candidate genes that 
contribute to tissue damage in SCD.  
Elevated inflammation and endothelial dysfunction have been well described 
in SCD. Particularly, pulmonary complications are the leading cause of mortality in 
SCD due to vaso-occlusive events that occur in the lung (21). To determine whether 
changes in gene expression patterns underlie pulmonary dysfunction in SCD, I 
performed a unbiased microarray screen in lung samples isolated from SCD and 
control mice. The gene categories with the highest log2 transformation values were 
inflammatory, heme and iron hemostatic genes, and circadian rhythmic genes. 
Several inflammatory-related genes identified in the screen include Ccl5, Ccl9, 
Ccl17, Cxcl2, Cxcl13, Ifi202b, C4b, C4a, Cxcl10, Pf4, Ccr2, Nfe212, Ccr4, Anxa1, 
Ptgs1, Tlr6, and Adam8.  A series of heme and iron metabolic genes upregulated in 
SCD lung were Lpn2, Slc25a37, Steap2/4, Fech, and Ltf. Unexpectantly, I 
discovered upregulated series of circadian rhythmic genes, which were Bhlhe40, 
Nr1d1, Nr1d2, Dbp, Per2, Id1, Id2, and Nampt. Although the reason as to why these 
genes are enhanced in SCD is unknown. I focused my attention on Per2, due to the 
role that Per2 gene expression plays in mediating cellular toxicity and inflammation 
(22-24). Moreover, PER2 is a transcription factor that regulates the transcription of 
genes responsible for anti-oxidative stress in multiple cell types (25). Overall, PER2 
is a major circadian clock gene that regulates biological clocks, which are 
responsible for generating circadian rhythms in multiple organs.  
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1.7. Circadian Period genes from fruit flies to mammals regulate circadian clock 
function. 
Period (Per) gene was initially discovered in drosophila in 1971 by Seymour 
Benzer and Ronald Konopka, which was later characterized as a circadian gene 
essential for locomotor function. Years later, three scientists, Dr. Jeffrey C. Hall, Dr. 
Michael Rosbash, and Dr. Michael W. Young earned the Nobel Prize for their 
pioneering work by identifying the function of Per as a circadian clock oscillator. 
Interestingly, Per mutants were identified to have a shortened or lengthened period 
length, which contributes to complete arrhythmicity in constant darkness (26).  Per 
was identified to oscillate in a circadian manner to regulate a transcriptional-
translational feedback loop (27). Mammalian Per genes were identified and cloned 
to generate mouse strains with genetically altered Per genes. Although there are 
three Per gene homologues that underlie circadian behavior in mice Per1 and Per2 
are the major genes that function independently in mediating circadian activity in 
rodents (28). Particularly, Per2 has been identified to function as a tumor suppressor 
in age-related toxicity, a contributor to heme biosynthesis, and a regulator of wheel-
running locomotive activity in mice (23, 29-31). The function of Per1 has been 
demonstrated to be involved in rodent circadian behavior (32)  and the role of Per3 
has not been fully understood.  
At the transcriptional-translational level, RNA and protein levels of clock-
related genes and proteins are circadian regulated. Circadian genes have specific 
rhythmic expression patterns, which can positively or negatively influence the 
peripheral clocks. Particularly, brain and muscle arnt-like 1 (BMAL) and circadian 
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locomotor output cycles kaput (CLOCK), are the upstream oscillators that bind to 
enhancer box (E-box) regulatory promoter regions (14). Thus, BMAL and CLOCK 
transcriptionally regulate  expression of Per1 and Per2 genes, which encode the 
downstream circadian oscillators. Elevated PER1/PER2 expression can 
transcriptionally repress BMAL/CLOCK expression in a negative feedback manner 
(15). Per expression can be further enhanced due to elevated enhancers binding to 
the E-box promoter regions to promote Per2 transcription (16). Circadian 
homologues, PER1 and PER2, play a vital role in maintaining the mammalian clock 
(25) (Illustration 2). In fact, transcriptional repression of Per2 is detrimental to overall 
clock function. Persistent repression or genetic deletion of Per2 impairs vital organ 
functions and contributes to disease progression (26, 27). 
Moreover, disruptions in circadian rhythms mediating biological clocks can 
contribute to  cardiovascular disease, neurological disorders, cancer, and obesity. In 
addition to Period (Per1 and Per2) genes, other genes that regulate circadian 
rhythms, which includes Cryptochromes (Cry1 and Cry2), Neuronal PAS domain 
protein 2 (Npas2), Nuclear receptor subfamily 1  group D member 1 (Nr1d1) , Brain 
and muscle arnt-like 1 (Bmal) and circadian locomotor output cycles kaput (Clock) 
(33) . All of these clock genes are ubiquitously expressed in the organism and are 
necessary for maintaining circadian rhythms (Illustration 2). Circadian rhythms are 
synchronized globally in the organism; moreover, tissue-specific circadian clocks are 
regulated in response to stimuli such as hormones, glucose, salt, cytokines, and 
chemokines (34). The circadian clock regulates expression of the inflammatory 
response that contributes to the onset of disease (35, 36). Synchronized circadian 
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rhythms persistently regulates peripheral clocks in tissues. Multiple cell types in 
tissue also express circadian genes that oscillate based on the time of day.  In fact, 
PER1 and PER2  play a critical role in hematopoiesis, which takes place in the bone 
marrow  (37). At the cellular level, synchronized rhythms can be observed in the 
erythroid, myeloid, and lymphoid cell lineages (35, 38, 39). However, in erythrocytes 
Per2 is not expressed due to enucleation.  Besides mature erythroid cells, other 
hematopoietic lineage cells with a nuclei can transcribe Per2 DNA, which play a role 
in various cellular processes (29).    
 
 
 
 
 
 
 
 
 
 
 
Illustration 2  
Biochemical Society Transactions 
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Illustration 2: Circadian oscillators regulate rhythmic processes in the cell 
(Biochemical Society Transactions). In the nucleus, BMAL and CLOCK bind to the 
Enhancer box (E-Box) promoter regions to promote transcription of Per1 or 2, Cry 1 
or 2, and Ck1ε. Elevated PER1/PER2 can negatively inhibit BMAL/CLOCK that 
regulate Per1 or 2 transcription. Retinoic acid receptor-related orphan receptors 
(ROR) binding to reverse response elements (RRE) contributes to Bmal 
transcription. However, elevated Rev-erβ can inhibit ROR binding to RRE to inhibit 
Bmal transcription. 
 
1.8. The rationale of this dissertation.   
The purpose of this dissertation is to investigate the detrimental impact of 
chronic hemolysis in SCD that mediates end organ damage. I investigated the role 
of S1P-mediated S1PR1 signaling in organs that contributes to multiple organ 
dysfunction.  Additionally, I performed a robust and unbiased microarray screen to 
determine how multiple organ damage due to elevated heme deposition in SCD 
contributes to changes in gene expression. Unexpectedly, I discovered that 
circadian Per2 gene expression was upregulated in SCD, which indicates that Per2 
gene expression mediate molecular clock function, which has an important role in 
this disease. Extending from the results identified from the unbiased screen, I have 
generated a hypothesis that elevated Per2-mediate biological clock function is 
required for overall organ maintenance in SCD. By generating sophisticated genetic 
tools by bone marrow transplantation studies, I will study the expression patterns of 
Per2 in sickle and control mice by means of a Per2  knock-in bioluminescence 
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reporter mice model to quantify PER2 luciferase activity. Additionally, I will determine 
whether the differentiation of bone marrow derived cell lineages in the periphery is 
altered by global deletion of Period genes in sickle mice.  Overall, I propose that 1) 
elevated Per2 plays a beneficial role in SCD due to essential role in regulating 
biological clocks in vivo. 2) Molecular clock dysfunction due to global Per1-/-/ Per2-/- 
in multiple cell types is detrimental and promotes tissue dysfunction in SCD. 3) 
Mixture of cell types that are Per1-/-/ Per2-/- in organs or Per1+/+/Per2+/+ progenitor 
cells from bone marrow can co-induce heme oxygenase 1 (HO-1) activity to regulate 
heme degradation, which play a protective role in the organ.  
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II. Methods 
 
2.1. Mice generation (Berkeley Human Sickle Cell, SCD-IL-6-/-, Per1/ Per2 dKO, 
Per2Luciferase mice). 
Animals were housed in 12 hour light/12 hour dark (12 L: 12 D) conditions 
and had access to food and water ad libitum. All animal procedures presented 
herein were approved by the Animal Welfare Committee at the University of Texas 
Health Science Center. IL-6-/- (IL-6 dKO) mice were used for mating whereas 
Per2Luciferase (Per2Luc) and Per1-/-/Per2-/- (Per1/Per2 dKO) mice were used as bone 
marrow (BM) recipients. WT,IL-6-/- , and SCD Berkeley mice were purchased from 
Jackson laboratory. SCD heterozygous (SCD Tg/+) females mated with SCD Tg/+ 
males. Progeny were genotyped to confirm the presence or absence of mutant 
sickle beta-globin (HbS) gene. About 25% of progeny is predicted to have mutant 
gene. SCD- IL-6-/- mice were generated by mating heterozygous SCD female mice 
with IL-6-/- male mice. Progeny were genotyped and confirmed to be heterozygous 
for three genes: hemoglobin alpha (HBα), hemoglobin beta (HBβ), and IL-6. 
Heterozygous Hbα -/+/ Hbβ -/+/ IL6-/+ females were mated with IL-6 dKO males 
(Hbα+/+/ Hbβ +/+/IL-6-/-). Progeny genotype as Hbα -/+/ Hbβ -/-/ IL-6-/-, were confirmed 
and recognized as SCD-IL-6-/- mice.  
Tails were collected for genomic DNA extraction. Primer sequences for HBB 
tm1TOW (Sickle cell) sequences were designed as followed (Table1) (40). 
Thermocycler conditions were set for 40 cyclers at 94 degrees for 5 minutes, 84 
degrees for 10 minutes, 94 degrees for 1 minute, 60 degrees for 30 seconds, and 72 
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degrees for 2 minutes. Followed by 72 degrees for 5 minutes and a final hold 
temperature at 4 degrees. Mutant and WT DNA fragments were analyzed by gel 
electrophoresis. Mutant DNA length (398 base pairs) and WT DNA length (291 base 
pairs). IL-6 primer sequences were designed as follow (Table 1) (41). Thermocycler 
program was set for 30 cycles for the following 94 degrees at 5 minutes, 84 degrees 
at 10 minutes, 94 degrees at 1 minute, 60 degrees for 30 seconds, and 72 degrees 
at 2 minutes. Then 72 degrees for 5 minutes and final holding temperature at 4 
degrees.  Gel electrophoresis was performed to detect WT (174 base pairs) and 
Mutant (380 base pairs) DNA fragments. 
Per1/Per2 dKO mice were a gift provided by Dr. Cheng Chi Lee and were 
maintained by mating Per1/Per2 dKO males and females. Progeny were genotyped 
to confirm mutated Per1 and Per2 gene expression. Mating strategy, homozygous 
Per1/Per2 dKO males crossed with homozygous Per1/Per2 dKO females.  Primer 
sequences for Per1 WT, Per1 null DNA,  Per2 WT, and Per2 null DNA were 
designed as followed (Table 1) (30). PCR conditions were set for 30 cycles of: 95 
degrees for 1 minute, 94 degrees for 38 seconds, and 63 degrees for 38 seconds. 
Then 72 degrees for 45 seconds and then 3 minutes, and a final hold at 4 degrees. 
Gel electrophoresis was performed to confirm WT Per1 DNA length is 440-448 base 
pairs and Null Per 1 DNA length is 280-320 base pairs. Primer sequences for Per2 
WT and Per2 Null DNA were designed as followed (Table 1) (30). PCR thermocycler 
conditions were set at to repeat for 30 cycles at 95 degrees for 1 minute, 94 degrees 
for 50 seconds, and 62 degrees for 50 seconds.  Followed by 72 degrees for 50 
seconds, 72 degrees for 3 minutes, and final hold temperature at 4 degrees. Gel 
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electrophoresis was performed to validate Per2 WT DNA (240-280 base pairs) and 
Per2 null DNA (600-640 base pairs).  
 
Per2Luicferase mice were provided by Dr. Seung-Hee Yoo. Heterozygous 
Per2Luciferase males mated with heterozygous females. Three primers sequences P1, 
P2, and P3 were designed to detect progeny genotype: WT (Per2 +/+), heterozygous 
(Per2 Luc/+), and mutant mice (Per2 Luc/Luc). WT allele (P1) or deleted allele (P2) 
detection using primer sequences (Table 1) (42). Reverse primer sequences for 
detecting luciferase knock-in allele (P3) (42). Tails were collected and processed for 
genomic DNA extraction. PCR thermocycler conditions were run at 95 degrees for 1 
minute, 55 degrees for 1 minute, and 72 degrees for 1 minute that repeated for 35 
cycles. Gel electrophoresis analysis was carried out to confirm DNA base pair sizes. 
Heterozygous and homozygous (Per2Luc/+ and Per2 Luc/Luc) mice were maintained 
and used as BM recipients.  WT DNA length was 230 base pairs and mutant DNA 
length 680 base pairs. Heterozygous mice express both WT and mutant DNA.   
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Table 1:  Genetic sequences for HBB tm1TOW (Humanized sickle cell mice), global 
deficient  IL-6 dKO, Per1/Per2 dKO (corresponding to gene sequences for null Per1, 
WT Per1, WT Per2, Per2gtnlf2, and Per2Neo4), and Per2Luciferase bioluminescence 
reporter mice (gene sequences were designed for detecting Per2Luciferase : P1, P2, 
and P3. Gene sequences were confirmed by Jackson Laboratory.    
 
2.2. Pharmacologic treatments in sickle mice.  
Sickle Cell Berkeley mice were treated with Fingolimod (FTY720) supplied by 
Cayman Chemical Company at a dose of 1 mg/Kg of body weight and injected 
intraperitoneally (IP) for up to 8 weeks. Drug was prepared in PBS (Invitrogen) used 
as a vehicle.  
 2.3. Hematological assessment in sickle mice. 
Mice were treated with isoflurane supplemented with oxygen as means of 
anesthesia during blood collection. Peripheral blood isolated from tail vein was 
collected in EDTA tubes in order to prevent coagulation. A hemolyzer (IDEXX 
technologies) was used to detect multiple hematological parameters that pertain to 
erythrocytes and immunological cells. For sickling assessment, a few drops of blood 
were smeared on microscope glass slides with positive charges coated on the glass, 
which improves cell adhesion on the slide. After blood dried on the slide, slides were 
stained with Wright-Giemsa solution, which stain erythrocytes pink. Sickle cells were 
captured on a 20X objective using a Zeiss light microscope.       
2.4. Erythrocyte lifespan measurements. 
18 
 
Biotinylated-labeled erythrocytes were generated in vivo to determine 
erythrocyte life span in SCD mice.  N-hydroxysuccinimide (50 mg/Kg) was injected 
into the retro-orbital plexus in mice. Next, peripheral blood (5 uL) was collected from 
mouse tail vein on day 1, 2, 3, 5, and 8 for flow cytometric detection of biotinylated-
labeled erythrocytes by expression of streptavidin conjugated fluorochrome and 
Ter119 (12, 43).  
2.5. Flow cytometric analysis of immune cells isolated from peripheral tissues. 
Whole tissues were isolated from euthanized mice. Tissues were harvested in 
culture dishes containing Hank’s media and were manually processed with sterilized 
surgical tools to generate single cell suspensions. Suspensions were transferred to a 
clean conical tube containing a 40-µm strainer in order to filter out unprocessed 
tissue clumps. Single cells were treated with Fc blocking antibody (BD Biosciences) 
per million cells for 30 minutes at 4 degrees centigrade as previously described (43). 
Afterwards, cells were stained with fluorophore-conjugated antibodies to detect 
S1PR1 and F4/80 as previously described (43).  Single cell fluorescent expression 
was detected using a Gallios Flow Cytometer (Beckman Coulter) and analysis was 
performed using Kaluza software (Beckman Coulter).  
2.6. Whole blood detection of circulating inflammatory cytokines by ELISA method. 
Whole blood was drawn from anesthetized mice by cardiac puncture and 
collected in anti-coagulant EDTA tubes. Blood was centrifuged to collect plasma as 
previously described (43). Multiple analyte ELISA array was performed to detect 
interleukin (IL): IL- 2, 6, 12, and 17A (MEM-004A; Qiagen).   
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2.7. IL-6 detection in serum, multiple organs, and bronchoalveolar lavage (BAL) 
fluid.  
              Mice were anesthetized and blood was collected by cardiac puncture, blood 
was centrifuged, serum was flash frozen, and stored at-80 degrees centigrade for 
future usage.  Skin and muscle was removed to expose the trachea. A small hole 
was cut in the trachea and a gauge needle was inserted.  1% BSA-PBS was injected 
into the trachea to collect bronchoalveolar lavage (BAL) fluid.  BAL fluid was flash 
frozen and stored until further usage.  Afterwards, whole spleen, lung, kidney, and 
liver were removed from euthanized mice and were properly preserved.  Murine IL-6 
detection in BAL, blood plasma, and multiple tissues was performed by ELISA assay 
based on manufacturer’s instructions (EZMIL-6, MilliporeSigma).  
2.8. Bone marrow derived macrophages generation from mouse. 
Mice were IP injected with 2.5% Avertin and euthanized by cervical 
dislocation. Skin and muscle was removed with sterilized scissors and forceps. 
Femur and tibia were removed from both hind legs and placed in Hank’s solution for 
further dissection. Excess tissue was removed from the bone and bone was clipped 
at both ends. Marrow found inside the bone was flushed out in a clean culture dish 
containing DMEM that is supplemented with FBS, L929, glutamine, and PenStrep. 
Cells were separated with clean pipet tip to prevent coagulation. Cells were collected 
from the dish and centrifuged. Then, the cell pellet was collected and resuspended 
in fresh media. Cells were counted and added to individual petri dishes with 
additional culture media for 4 days in a 37 degrees centigrade incubator.  Additional 
medium was added to cells in the petri dishes on day 4 and remained in culture 
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conditions for up to 4 additional days. Culture media was discarded on day 8 and 
fresh medium was added to petri dish. Cell confluence was determined at 80 to 
90%.  
2.9. Pharmacologic treatment in macrophage culture for S1P, W146, JTE013, 
TY52156, CYM50358, and AG490. 
Mouse BM derived macrophages were prepared as previously described (43). 
Macrophage cultures were treated with 1uM of S1P prepared in vehicle and S1PRs 
antagonists for S1PR1, S1PR2, S1PR3, S1PR4, refer to as W146, JTE013, 
TY52156, CYM50358, respectfully. Additionally, antagonist for JAK2 is refer to as 
AG490.   
2.10. Whole lung RNA isolation for gene expression screening. 
SCD and WT control mice were euthanized by cervical dislocation and whole 
lung was removed. Lung tissues were completely homogenized in TRIzol 
(Thermofisher) reagent and kept on ice. Chloroform was added to homogenized 
samples and centrifuged to create phase separation. RNA was treated with DNase 
for 30 minutes in order to prevent degradation. RNA was precipitated with 
isopropanol and RNA samples were transferred to mini columns from RNeasy micro 
kit (Qiagen) for RNA purification. RNA quality checks were accessed using nanodrop 
(ThermoFisher) and bioanalyzer (Aligent 2100 technologies). RNA quality control 
(QC) were based on 260/280 ratio of ≥ 2 and RNA integrity number (RIN) of ≥8. 
Samples passing all QC requirements were used for microarray analysis. Lung RNA 
samples were reverse transcribed (RT) to generate cDNA and newly synthesized 
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cDNA were fluorescently tagged. DNA was hybridized to GeneChip Mouse Exon 1.0 
ST (Affymetrix). Data was imported to GeneChip software in order to calculate 
intensity values based on fluorescence detection. Data files were imported to 
Affymetrix expression console software to detect probe fluorescence ratios used to 
confirm quality of library preparation. Intensity values were log2 transformed and 
data was imported to software for further statistical analysis. Statistical significance 
was based on P values of P<0.05 and fold changes of differentially expressed genes 
were determined in SCD versus WT group.  
2.11. Irradiation and bone marrow (BM) transplantation. 
WT and SCD humanized Berkley (SCD Tg) mice were used as BM donors. All 
donors were at least 9 weeks of age prior to BM transplantation (BMT).  Recipients 
with confirmed genotypes were treated with 0.2 % Neomycin for at least 24 hours 
prior to irradiation and were maintained on Neomycin treatment for up to 2 weeks 
after irradiation. Recipients were treated with 2 rounds of toxic 2Gy (500 RAD) 
irradiation that took place 3 hours apart. Irradiated mice were injected retro-orbitally 
with SCD or WT BM (1 X10 6 million) cells.  At 8 weeks post BMT, 50 uL of whole 
blood from tail vein was collected in EGTA tubes. Blood cells were lysed using 
ammonium chloride (NH4Cl) and washed with phosphate buffered saline (PBS) 
supplemented with fetal bovine serum (FBS). Cells were stained with leukocyte 
markers to detect CD45.1- phycoerythrin (PE) and CD45.2- fluorescein 
isothiocyanate (FITC) expression by flow cytometric analysis. To confirm BM 
chimeras, SCD transplanted mice typically express high expression of CD45.1 
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whereas WT control transplant mice groups would express elevated expression of 
CD45.2 on leukocytes populations.  
2.12. PER2 luciferase detection in bioluminescence reporter mice. 
Whole lung was isolated from euthanized mice. Lung biopsies were placed on 
MilliCell membrane inserts then placed inside a culture dish. Biopsies were cultured 
in DMEM medium that was supplemented with 10 mM HEPES, 
penicillin/streptomycin (PenStrep), 2% B27, and 0.1 mM of Luciferin. Cultures were 
tightly sealed with vacuum grease and secured with a coverslip, then placed inside a 
tightly fasted- light protected 36 degrees incubator for up to 4 days. Tissue 
sustaining bioluminescence was continuously monitored by LumiCycle 32 
(ActiMetrics) photomultiplier tubes for detecting photon counts. Analysis was 
performed using LumiCycle software (Actimetrics). 
2.13. Hematoxylin and eosin (H&E) staining of multiple tissues. 
Mice were anesthetized using 2.5% Avertin. Whole blood was collected by 
means of cardiac puncture. Cardiac profusion was performed in mice to remove 
excess blood in the circulation. Whole lung, liver, and spleen were removed from 
mice and placed in 10% formalin. Organs were processed in a series of ethanol 
washes that increased to 100% ethanol then placed in histoclear, a wax removing 
agent.  Organs were fastened to a plastic mold for the paraffin wax embedding 
process. Paraffin embedded organs were allowed to cool over night at room 
temperature.  Tissues were sectioned at 4 microns using a Leticia microtome. 
Tissue sections were deparaffinized in histoclear followed by a decreasing series of 
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ethanol solutions. Sections were stained in hematoxylin solution to stain cell nuclei 
that was followed by eosin solution to stain the cytoplasm and fibers in tissue. 
Sections were placed in differentiation solution to increase stain quality. Tissue 
sections were mounted using Cytoseal, a mounting agent, and coverslips were 
placed to secure the sections. Images were acquired using an Olympus BX60 
microscope at a 20X objective. 10 to 15 images were taken for each slide to 
examine tissue structure, necrotic areas, and inflammatory infiltrate. Images were 
analyzed using Photoshop and semi-quantification was performed using Image J to 
examine area density of inflammatory and necrotic regions of the tissues.  
2.14. Perl’s Blue Prussian iron staining of multiple tissues. 
Tissue sections of the lung, liver, and spleen were deparaffinized as 
previously described in section 2.9. Sections were placed in equal part of 
hydrochloric acid (HCL) and potassium ferrocyanide K4Fe(CN)6 solution. Tissues 
were rinsed in distilled water and placed in nuclear fast red solution then rinsed in 
water. Tissue iron expression was identified by enhanced blue color and cell nuclei 
stain as pink. 
 2.15. Proteinuria detection. 
 Mice were individually placed in metabolic cages (Tecniplast 3600M021) for 
24 hours and had access to food and water ad libitum. Urine was collected and 
briefly centrifuged to remove feces, food, and other contaminates. Urine samples 
and standards were placed in a microplate followed by addition of picrate working 
solutions prepared using 1 M NaOH and Picrate Reagent. Microplate was placed in 
24 
 
a plate reader and absorbance was detected at 500nm.  Collected urine and 
standards were placed in microplate for albumin (Exocell) measurements. Mouse 
anti- mouse albumin was added to samples and incubated at room temperature. 
Urine albumin levels were confirmed by chemiluminescent detection using anti-rabbit 
–horse radish peroxidase (HRP). Color intensity was measured 
spectrophotometrically. Normalizations were performed by albumin per mg of 
creatinine.  
 2.16. Hemolytic analysis for total bilirubin.  
Whole blood was collected by means of cardiac puncture from anesthetized 
mice.  Blood was spun down at 2500 RPM for 5 minutes. Blood plasma was 
collected, buffy coat was discarded, and erythrocytes were stored. Plasma was 
placed in microplate along with working reagents. Spectrophotometric 
measurements were detected at 530 nm. Total bilirubin detection was calculated 
based on manufacturer’s instruction (BioAssay). 
 2.17. Alanine aminotransferase (ALT) detection.  
Whole blood was collected and plasma was isolated as previously described 
in section 2.12. ALT enzyme activity was measured by generation of pyruvate that 
was assessed by colometric/ fluorometric analysis. Quantifications were performed 
based on manufacturer’s instructions (Sigma Aldrich).    
  2.18. Neutrophil infiltration in lung tissue. 
Lung sections were deparaffinized in a series of ethanol washes and 
rehydrated as previously described in section 2.9.  Tissue sections were heated in 
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citrate acid antibody retrieval solution for 30 minutes and were allowed to cool to 
room temperature. Lung tissue sections were incubated in 3% hydrogen peroxide 
solution to block endogenous peroxidase activity. Tissue sections were then blocked 
in 2% BSA-PBS solution for 1 hour and were incubated with primary anti-mouse 
Ly6-G 1:200 diluted (BD Biosciences) antibody overnight at 4 degrees, washed, and 
incubated in biotinylated anti-mouse antibody. Development was performed using 
DAB peroxidase substrate solution (Vectastain), counterstained, washed, and 
mounted. Images were acquired on 20X objective on an Olympus microscope.  
2.19. RNA extraction and semiquantitative polymerase chain reaction (PCR) 
detection of inflammatory genes in lung. 
Whole lung tissues were isolated from euthanized mice. Lung were 
homogenized in TRIzol (thermofisher) solution, DNase treated to prevent RNA 
degradation, and precipitated in isopropanol. RNA were purified using RNeasy micro 
kit (Qiagan) based on manufacturers’ instruction.  Quality checks of RNA samples 
were confirmed by nanodrop (Thermofisher). Absorbance 260/280 ratio of ≥ 2 
passed quality check for RNA quality. 1 µg of RNA were revere transcribed to 
generate cDNA. Primers for semiquantitative PCR were design using (Integrative 
DNA technologies) software. Sybr Green (Qiagan) probe were used for gene 
expression detection for mouse Bmal and Per2 (44). Mouse IL-6 (45), mouse Tlr4 
(46), and mouse β-actin were also detected by RT-PCR. PCR thermocycler 
conditions were set at 95 degrees for 1 minute, 60 degrees for 30 seconds, and 72 
degrees for 15 seconds.  Gel electrophoresis were performed to detect DNA 
fragments for each gene.  
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Table 2 
 
Gene Forward Reverse 
Mouse Bmal  
 
5’- 
CCAAGAAAGTATGGACAC
AGACAAA -3’ 
5’- 
GCATTCTTGATCCTTCCTTG
GT -3’ 
Mouse Per1  5’- 
CCCAGCTTTACCTGCAGA
AG-3’ 
 5’- 
ATGGTCGAAAGGAAGCCTC
T -3’ 
Mouse Per2 5’- 
TGTGCGATGATGATTCGT
GA-3’ 
5’- 
GGTGAAGGTACGTTTGGTT
TGC-3’ 
Mouse IL-6  5’-
TAGTCCTTCCTACCCCAAT
TTCC-3’ 
 5’-
TTGGTCCTTAGCCACTCCTT
C-3’ 
Mouse Tlr4  5’-
TGGCTGGTTTACACATCC
ATCGGT-3’ 
5’-TGG 
CACCATTGAAGCTGAGGTC
TA-3’ 
Mouse β-actin  5’- 
CCAGAAGGACTGTTATGT
GGGA-3’ 
5’- 
GACTCCGTGTTCAATGGGA
TAC-3’ 
 
 
Table 2: List of genes for Bmal, Per1, Per2, IL-6, Tlr4, and β-actin in mouse. Primer 
sequences were designed as previously described (44, 46). 
 
2.20. Immunofluorescence detection of heme oxygenase (HO-1) expression in 
alveolar macrophages. 
Whole lung sections were processed for deparaffinization and rehydration 
followed by antibody retrieval treatment as previously described in sections 2.9 and 
2.14. Tissue sections were blocked in 2% BSA-PBS followed by overnight incubation 
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of diluted antibodies mouse anti- rabbit HO-1 (1:200) (Cell signaling) and mouse 
anti-rat F4/80 (1:200) (Abcam). Sections were washed several times followed by 
incubation of diluted (1:1000) goat anti-rabbit IgG and donkey anti-rat IgG (H+L) 
(Thermofisher). Lung sections were washed to remove excess antibodies and 
mounted with DAPI SlowFade Gold Antifade reagent (Thermofisher). Clear color nail 
polish were placed around the perimeter of the section slide to secure coverslip on 
slide.  
 
2.21. Statistical analysis. 
Analyses were performed using Graph Pad software (LaJolla, California).  
Student t tests for 2 group analyses or one-way ANOVA followed by Tukey multi-
comparison tests were performed for multiple group analyses.  *P<0.05 were 
considered significant. 
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III. Results 
 
 3.1. Chapter 1: Chronic inflammation and multiple tissue 
damage is detrimental in SCD 
 
This chapter is based upon: Zhao S, Adebiyi MG, Zhang Y, Couturier JP, Fan X, 
Zhang H, Kellems RE, Lewis DE, and Xia Y. Sphingosine-1-phosphate receptor 1 
mediates elevated IL-6 signaling to promote chronic inflammation and multitissue 
damage in sickle cell disease. FASEB J. 32,000–000(2018)(43), with permission 
from the FASEB journal for the usage in this dissertation.  
 
Unbiased metabolomics analysis revealed an increase of sphingosine-1-
phosphate (S1P), a highly reactive bio-lipid, in the blood circulation of SCD mice and 
patients (12). Extracellular S1P signals via five G-protein coupled receptors 
(GPCRs) known as S1P receptors (S1PRs). S1P-S1PRs signaling has been 
identified to contribute to disease-related conditions, including vasculature leakage, 
tissue injury, and pain (47-49). Amongst the five S1PRs, S1PR1 is ubiquitously 
expressed in multiple cell types and organs and has a high affinity for S1P (50, 51). 
Although sphingosine kinase 1(SphK1) –mediated S1P production is independent of 
sickling (12), the question remains whether S1P-mediated S1PR1 activation 
contributes to sickling and further SCD progression.  
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3.1.1. FY720-mediated S1PR1 antagonism has no effect on erythrocyte sickling.  
FTY720 is a FDA-approved drug to treat relapsing multiple sclerosis known to 
have potent anti-inflammatory effects in experimental animal models (15). 
Sphingosine kinases phosphorylate FTY720 in vivo, which mimics the chemical 
structure of S1P. Thus FTY720 can target S1PRs to either promote recycling of the 
receptor to membrane or receptor degradation (52). S1PR1 is ubiquitously 
expressed in multiple cell types including endothelial and immune cells, which 
contributes to inflammatory responses such as cytokine secretion mediated by 
inflammatory cell infiltration to multiple organs that promote disease (53).   
Sickle erythrocytes have a much higher turnover than normal erythrocytes.  I 
tested whether FTY720 improves erythrocyte life span in sickle mice. To test this, I 
treated SCD mice with FTY720 (1 mg/Kg/day in vehicle, intraperitoneal injection) or 
saline-vehicle injection for a duration of 8 weeks. I collected peripheral blood by tail 
vein extraction from treated mice groups. I used flow cytometry to detect fluorescent 
streptavidin used to identify biotinylated-labeled erythrocytes generated in vivo by 
means of injecting N-hydroxysuccinimide (50 mg/Kg) in treated SCD mice.  
Erythrocytes were isolated from the treated mice on day 1, 2, 3, 5, and 8, which 
followed N-hydroxysuccidnimide injection to monitor erythrocyte life span.  No 
differences were observed in erythrocyte life span in FTY720 treated mice compared 
to control (Figure 1) (43).  
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Figure 1. FTY720 does not affect erythrocyte life span in SCD mice.  Mice were 
injected with N-hydroxysuccinimide (50 mg/Kg) to monitor erythrocyte life span. 
Whole blood was extracted from tail vein on 1, 2, 3, 5, and 8 days to detect 
biotinylated erythrocytes in sickle mice treated with FTY720 or saline.  Analysis 
revealed that FTY720 or saline treatment has no direct effect on erythrocyte life 
span in sickle mice; N=6-7 mice per group. 
Since I observed no differences in erythrocyte life span in FTY720 treated 
SCD mice, I examined other hematological parameters such as erythrocyte count 
(RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), and 
red cell distribution width (RDW), in the treated groups. Based on the complete 
blood cell (CBC) analysis, sickle mice express RBC levels of ~4 to 6 M/µL, HGB 
levels of 6 to 8 g/dL, HCT levels of 18 to 27%, MCV levels of 40 to 50 fl, and RDW 
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levels of ~30 %. By contrast, WT mice typically express RBC levels of ~9 M/µL, HGB 
levels of ~13 (g/dl), HCT levels of 40 to 45 % and MCV levels of ~50 fl.  In the 
FTY720 treated SCD mice, there were no differences in RBC, HGB, HCT, MCV, or 
RDW compared to saline-treated SCD mice (Table 3) (43). I determined the 
morphology of erythrocytes in sickle mice to confirm the percentage of sickling in 
these mice. The analysis revealed that there were no differences in sickling in 
FTY720 treated mice compared to saline treated mice (Table 3) (43).  Altogether, I 
conclude that FTY720 does not significantly impact erythrocyte life span or reduce 
erythrocyte sickling in SCD mice. 
 
Table 3 
 
Table 3: SCD Tg: sickle cell disease transgenic mice; RBC: red blood cell count; HB: 
hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; RDW: red blood cell 
distribution width; WBC: white blood cells; LY: lymphocyte; NE: neutrophil; MO: 
monocyte; EO: Eosinophil; BA: basophils. * P<0.05 vs. SCD Tg mice without 
treatment. 
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3.1.2. Sphingosine-1-phosphate receptor 1 (S1PR1) mediates elevated inflammation 
in SCD. 
Although I detected no significant differences in erythrocyte sickling in SCD 
mice treated with FTY720, I discovered that circulating immune cells in FTY720-
treated mice were significantly reduced compared to saline-treated mice. The CBC 
analysis revealed that the total white blood cells (WBCs) that include lymphocytes 
(LYs), neutrophils (NEs), monocytes (MOs), eosinophils (EOs), and basophils (BAs) 
were reduced in FTY720 treated mice. Sickle mice express elevated levels of WBC 
~27 k/µL,  LY ~ 20 k/µL, NE ~4 k/µL , MO k/µL ,~0.09  EO k/µL, and  BA ~0.04 k/µL 
(Table 3) (43) .  However, FTY720 treated SCD mice express reduced levels of 
WBC ~ 8 k/µL, LY ~5 k/µL, NE ~2 k/µL, MO ~0.60 k/µL, EO ~0.12 k/µL, and BA 
~0.01 k/µL (Table 3) (43).   
 
 Since I revealed that the mechanism of action of FY720 in SCD functions in 
an immunomodulation capacity, I hypothesized that elevated S1PR1-mediates 
cytokine secretion from immune cells to contribute to systemic immune response 
and further SCD progression. To test this, I detected interleukin (IL)-2, -6, -12, and -
17A levels in peripheral blood by ELISA. Although multiple cytokines were increased 
in SCD mice compared to WT mice, IL-6 was induced to the greatest extent 
compared to the other cytokines (Figure 2) (43). Additionally, I revealed that all of 
the cytokines were reduced by FTY720 treatment in SCD mice (Figure 2) (43).  
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Figure 2. FTY720-treated SCD mice reduced circulating inflammatory 
cytokines demonstrated by ELISA assay. Values expressed as ± SEM, *P<0.05, 
SCD mice treated with FTY720 compared to SCD mice treated with saline. **P< 
0.01, SCD mice treated with FTY720 compared to SCD mice treated with saline. N= 
6-9 mice per treatment group.  
 
Further induction of circulating IL-6 in periphery was identified in SCD mice 
and reduction of IL-6 was observed in SCD-FTY720 treated mice. Next, I determined 
whether IL-6 in peripheral tissue levels correlated with plasma levels of IL-6.  To test 
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this, I isolated spleen, liver, lung, and kidney from FTY720 or saline treated WT and 
SCD mice to determine IL-6 protein levels. In comparison to elevated circulating IL-6 
levels in SCD mice, FTY720-treated mice showed a reduction of IL-6 expression in 
the periphery (Figure 3A). Additionally, IL-6 expression in multiple organs was  
elevated in SCD mice and reduced by FTY720 (Figure 3B). Taken together, I 
revealed that elevated FTY720 functions as an immune suppressor to reduce 
systemic and local inflammatory response in SCD.  
 
 
 
 
 
 
 
 
Figure 3. Circulating IL-6 and IL-6 protein levels in spleen, liver, lung, and 
kidney detected by spectrophotometric analysis. (A&B) Significant reduction of 
peripheral IL-6 and tissue IL-6 levels in mice treated with FTY720. *P < 0.01, WT 
mice treated with FTY720 compared to WT mice treated with saline or SCD mice 
treated saline compared to WT mice treated with saline, respectfully. **P < 0.05, 
SCD mice treated with saline compared to WT mice treated with saline or SCD mice 
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treated with FTY720 compared to SCD mice treated with saline. #P<0.001, SCD 
mice treated with FTY720 compared to SCD mice treated with saline; N=6-9 mice 
per group.  
 
 
3.1.3. Elevated interleukin 6 (IL-6) contributes to chronic inflammation and tissue 
damage in SCD. 
Interleukin 6 (IL-6) is a pro-inflammatory cytokine elevated in SCD (54). To 
determine whether elevated IL-6-mediate an inflammatory responses in SCD, I 
generated SCD mice with a global deficiency of IL-6 (SCD-IL6-/- as described in 
Methods Section of this dissertation. I analyzed CBC to examine hematological 
parameters. In SCD-IL-6-/-  mice, RBC counts ~6 M/µL, HGB ~6 g/dl, HCT ~20%, 
MCV ~48, and RDW ~34% (Table 3) (43). I detected erythrocyte sickling in SCD-IL6-
/-  and confirmed that there was no differences in sickling as previously observed 
(Table 3) (43).   
However,  I observed that SCD-IL6-/-  reduction of  WBCs ~ 15 k/µL, LYs ~ 11 
k/µL, NEs ~2 k/µL, MOs 1 k/µL ,~0.09  EOs k/µL, and  BAs ~0.04 k/µL (Table 3) 
(43).  This implies that genetic deletion of IL-6 in sickle mice reduces the immune 
response. To further confirm IL-6 global deletion in SCD mice, I detected circulating 
IL-6 levels and confirmed total elimination of IL-6 in SCD-IL6-/- (Figure 4) (43).  
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Figure 4.  Global genetic deletion of IL-6 in SCD mice abolished IL-6 levels in 
the circulation. Although SCD transgenetic mice showed increase plasma IL-6 
levels compared to WT mice. Sickle mice with global genetic deletion of IL-6 was 
generated and IL-6 plasma levels were not detectable in these mice.  Values shown 
represent the mean ± SEM.*P<0.01, SCD mice compared to WT mice. ND means 
not detected.  
 
Next, I determined whether elevated IL-6 contribute to tissue damage in SCD. 
Since systemic inflammation is evident in SCD mice and FTY720 mediates anti-
inflammatory effects, I hypothesized that FTY720-mediate IL-6 contributes to tissue 
damage in SCD.  To test this, I performed histological assessments in lungs, livers, 
spleens, and kidneys. I further quantified the areas of interests that indicate severe 
tissue damage in WT and SCD untreated mice, SCD mice treated with FTY70 or 
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saline, and SCD-IL-6-/- mice. Elevated inflammatory infiltrates in the lungs and 
necrotic areas in the spleens, livers, and kidneys was identified in SCD mice 
compared to WT mice (Figure 5 A-D) (43). Moreover, FTY720-treated SCD and 
SCD-IL-6-/- mice showed overall improved tissue structure and decreased 
inflammatory cell congestion in the lungs (Figure 5A-D) (43).  Reduced necrotic 
regions in spleens, kidneys, and livers was also observed in FTY720 treated SCD 
mice and SCD-IL-6-/- mice (Figure 5A-D) (43).  
Sickle mice and patients have severe kidney dysfunction due to abnormal 
glomerular filtration rates and elevated protein concentrations in the urine (10). I next 
examined kidney function in the pharmacologic treated SCD mice and SCD mice 
with IL-6 global deficiency  by detecting albumin normalized to creatinine levels in 
urine isolated from these mice. I first confirmed an increase of albumin in SCD saline 
treated mice and SCD untreated mice (Figure 5F) (43).  In comparison to the 
untreated and control treated SCD mice, I found that kidney function was improved 
FTY720 treated SCD mice and SCD-IL-6-/-  mice (Figure 5F) (43). 
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Figure 5.  FTY70 treatment or global genetic deletion of IL-6 contributed to 
overall improved multiple tissue dysfunction in SCD mice. (A) Histological 
assessments in untreated WT, untreated and treated SCD mice, and SCD-IL-6-/- 
mice. (B-E) Semiquantification of histological areas of interests in lung, spleen, liver, 
and kidney isolated from the multiple groups. (F) Quantification of kidney dysfunction 
in WT, SCD, and SCD-IL-6-/-  mice. *P<0.01, saline treated SCD mice compared to 
saline treated WT mice. **P<0.05, FTY720 treated SCD mice compared to saline 
treated SCD mice or untreated SCD mice compared to SCD-IL-6-/- mice.  
 
3.1.4. FTY720 mediates the reduction of S1PR1 in tissue macrophage. 
Since S1PR1 is expressed in various immune cell types and elevated S1P-
S1PR1 signaling contributes to chronic disease, I asked whether S1PR1 signaling in 
macrophages mediate tissue damage in SCD. To test this, I isolated tissue 
macrophages from kidney and spleen in FTY720 treated mice compared to saline-
treated mice. Next, I performed flow cytometric analysis to detect S1PR1 in tissue 
macrophages isolated from WT and SCD mice. At first, I observed that sickle mice 
express more S1PR1 on macrophages compared to WT mice (Figure 6A & B) (43). 
All peripheral macrophages express S1PR1, therefore, I detected S1PR1 expression 
in macrophages isolated from FTY720 treated SCD mice compared to FTY720 
treated WT mice. Taken together, I confirmed a further reduction of macrophages 
expressing S1PR1  in SCD treated mice (Figure 6A &B) (43).   
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Figure 6. FTY720 mediates reduction of S1PR1 in SCD peripheral 
macrophages. (A &B) Flow cytometric analysis of F4/80 + cells (macrophage 
marker) in spleen and kidney isolated from WT and SCD mice treated with FTY720 
or saline. *P<0.01, WT mice treated with saline versus WT mice treated with 
FTY720; *P<0.05, SCD mice treated with saline versus WT mice treated with saline. 
# P<0.001, SCD mice treated with FTY720 versus SCD mice treated with saline.  
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3.1.5. Elevated IL-6 contributes to induction of S1PR1 in SCD.  
As previously demonstrated, S1PR1 in macrophages is elevated in sickle 
mice and was reduced following FTY720 treatment. Since sickle mice with a genetic 
deletion of IL-6 show an overall improved multiple tissue structure and kidney 
function, I detected S1PR1 expression in kidney and spleen isolated from SCD-IL-6-/- 
mice.  By flow cytometric analysis, I detected S1PR1 in tissue macrophages from 
WT or SCD untreated mice and SCD-IL-6-/- mice. As expected, elevated expression 
of S1PR1 in macrophages were identified in SCD versus WT untreated mice (Figure 
7) (43). However, reduced S1PR1 was observed in SCD-IL-6-/- mice (Figure 7) (43). 
Therefore, I demonstrated that IL-6 mediates elevated S1PR1 in SCD tissue 
macrophages.  
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Figure 7. Reduction of S1PR1 expression in IL-6 genetic deletion mice. (A&B)  
Flow cytometric detection of S1PR1 in spleen and kidney tissue macrophages from 
untreated WT or SCD mice and SCD-IL-6-/- mice.  Induced S1PR1 expression was 
detected in SCD mice compared to WT mice. However, reduced S1PR1 expression 
in tissue macrophages was confirmed in SCD-IL-6-/- mice. Values present represent 
means ±SEM. *P<0.05, WT mice versus SCD mice; **P<0.05, SCD mice versus 
SCD-IL-6-/- mice.  
 
3.1.6. S1P-mediated S1PR1 activation upregulates IL-6 to promote further induction 
of S1PR1 regulated in a JAK2-dependent manner.  
As previously demonstrated, S1PR1 is involved in inducing IL-6 in SCD as 
identified by pharmacologic and genetic evidence. I determined whether IL-6 can 
mediate further induction of S1pr1 gene expression in macrophages. To test this, I 
generated bone marrow (BM)-derived macrophages from WT mice as described in 
the Methods Section of this dissertation. I stimulated BM-derived macrophages with 
S1P and measured IL-6 mRNA levels.  As predicted, I observed induction of IL-6 
mRNA and protein levels in S1P-stimulated macrophages (Figure 8 A &B) (43). To 
determine whether a specific S1PR mediates induction of IL-6, I treated 
macrophages with S1P and antagonists for S1PR- 1, 2, 3, and 4 (W146, JTE013, 
TY52156, and CYM50358), respectively. I discovered that macrophages treated with 
S1PR1 antagonists W146 and FTY720 reduced IL-6 mRNA and IL-6 protein level 
(Figure 8 A &B) (43).  For S1P-stimulated macrophages treated with JTE013, 
TY52156, or CYM50358 expressed no obvious differences in IL-6 levels (Figure 8 A 
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&B) (43). This indicates that the other S1PRs have no role in mediating IL-6 
induction in WT mice. 
To determine whether IL-6-mediates S1pr1 mRNA induction, I generated BM-
derived macrophages from WT and IL-6-/-  mice. I stimulated the WT and IL-6-/- 
macrophages with S1P to induce S1pr1 gene expression. I observed that S1P-
stimulated WT macrophages led to further induction of S1pr1 mRNA levels whereas 
reduction of S1pr1 mRNA levels was detected in IL-6-/- macrophages (Figure 8 C) 
(43). Moreover, I treated the S1P-simulated WT and IL-6-/- macrophages with 
FTY720 and W146 to antagonize S1PR1. I discovered that IL-6-/-  macrophages 
expressed reduced S1pr1 mRNA levels compared to WT macrophages (Figure 8 C) 
(43).  
 Additionally, I measured IL-6 mRNA and IL-6 protein levels in S1P-stimulated 
WT macrophages. As expected, I discovered that IL-6 levels were further induced in 
WT macrophages treated with S1P compared to vehicle (Figure 8 D &E) (43).  Since 
I observed an induction of S1P-mediating elevated IL-6 expression in WT 
macrophages, I asked whether S1P regulates IL-6 signaling.  To test this, I 
stimulated WT macrophages with S1P then treated macrophages with JAK2 specific 
inhibitor AG490. JAK2 is a tyrosine kinase that stimulates IL-6 production. I found 
that IL-6 mRNA and IL-6 protein levels were reduced in S1P-stimulated WT 
macrophages treated with AG490 (Figure 8 D &E) (43). 
Next, I determined whether JAK2 mediates S1pr1 gene upregulation in WT 
macrophages.  I tested this by stimulating WT macrophages with S1P and S1pr1 
mRNA expression in macrophages with or without addition of AG490. I found that 
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S1pr1 levels were reduced in WT macrophages treated with AG490 compared to 
S1P-stimulated macrophages without the addition of AG490 (Figure 8 F) (43).   
Overall, I demonstrated that S1P production mediates upregulation of S1PR1 
in SCD. By pharmacologic and genetic tools, I have shown that FTY720-treatment 
and genetic IL-6 deletion reduces multiple tissue injury, improves overall kidney 
dysfunction, and reduces chronic inflammation in SCD (Figure 8 G) (43). 
Mechanistically, I provided pharmacologic evidence that elevated S1pr1 gene 
expression can be blocked by S1PR1 antagonism using FTY720 and JAK2-inhibtion 
by AG490 in macrophages (Figure 8 G) (43).  
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Figure 8.  S1P-activates S1PR1 to promote IL-6 production, which upregulates  
 
 
 
 
 
 
 
 
 
 
Figure 8 
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Figure 8. IL-6 production, which  induces S1pr1 mRNA levels in a JAK2-
dependent manner in mouse BM-derived macrophages. (A &B) WT BM-derived 
macrophages were stimulated with S1P in the presence or absence of antagonists 
for S1PR-1, 2, 3, and 4 followed by a determination of IL-6. (C) WT and IL-6-/-  BM-
derived macrophages were generated to detect S1pr1 mRNA expression. (D &E) 
WT macrophages stimulated with S1P in the presence or absence of  JAK2 inhibitor 
AG490 followed by the determination of  IL-6 mRNA and protein levels. (F)  S1pr1 
mRNA levels were detected in S1P-stimulated WT macrophages treated with 
AG490. Values represent mean ± SEM (N= 6 per group).  (G) Summary of overall 
findings in this work. *P <0.01, S1P-treated WT macrophages compared to vehicle-
treated group. ** P<0.05, S1P-treated group compared to FTY720-treated group, 
S1P-treated group compared to W146-treated or FTY720-treated group, and S1P- 
treated group compared with AG490-treated group (43).  
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Overall, I provided evidence that elevated S1P-S1PR1-underlines IL-6 
induction in macrophage to contribute to systemic and local inflammation in sickle 
mice. By generating SCD-IL-6-/- mice, I demonstrated that IL-6 mediates prolong 
inflammation, which contributes to further upregulation of S1pr1 mRNA expression in 
tissue macrophages. To further demonstrate this mechanism, I generated murine 
BM-derived macrophages to confirm the roles of S1PR1 and IL-6. By antagonizing 
S1PRs in macrophages, I detected IL-6 levels and I found that S1PR1 antagonists 
reduced IL-6 levels whereas the other S1PRs did not. Moreover, I demonstrated that 
IL-6 mediates the upregulation of S1pr1 mRNA expression in a JAK2-dependent 
manner, which confirms the molecular mechanism.   
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3.2. Chapter 2: Elevated circadian Period 2 is beneficial in SCD  
 
This chapter is based on unpublished work by Adebiyi MG, Zhao Z, Youqiong Y, 
Manalo J, Hong Y, Hill R, Gong J, D’Alessandro A, Lee CC, Xian W, McKeon F, 
Kellems RE, Yoo SH, Han L, and Xia Y.  
 
In this chapter, I will present the robust genetic screen I performed in SCD 
mice compared to WT control mice. Several upregulated pathways in SCD were 
identified that involve genes in heme metabolism and inflammation. Unexpectantly, I 
discovered upregulated expression of circadian clock genes in SCD. The role of 
circadian genes in SCD has not been previously studied. This chapter will explore 
the role of a circadian gene Period 2 and its role in SCD.  
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3.2.1. Upregulated expression of circadian genes, inflammatory genes, heme and 
iron homeostatic genes in SCD lung. 
Elevated inflammation, vasculature dysfunction, and overall multiple tissue 
injury is well described in SCD (16, 55). Tissue injury in SCD is a detrimental 
consequence of the disease progression, which is often irreversible. In fact, changes 
in gene expression due to chronic tissue injury reveals how an organ functions.  To 
determine whether changes in gene expression underlie tissue dysfunction in SCD, I 
performed a robust unbiased microarray genetic study as a strategy to examine 
gene expression profile in SCD mice compared to WT control mice. I selected the 
lung as an organ of interest because pulmonary complications are the leading cause 
of SCD patient mortality in the clinic. I isolated RNA from SCD and WT lung then 
reverse transcribed the RNA to generate cDNA. High quality SCD and WT samples 
were used to prepare cDNA libraries and screen for gene detection using Affymetrix 
expression array.  
In the screen, I identified ~ 700 genes specific to lung isolated from SCD and 
WT mice. Amongst the genes identified, I discovered that ~ 200 genes were 
upregulated in the SCD lung compared to WT lung.  By performing pathway 
analyses, I revealed lung specific genes involved in cilium movement, chemokine-
mediated signaling pathway, immune response, axoneme assembly, chemotaxis, 
inflammatory response, cellular response to interleukin-1, response to virus, 
neutrophil chemotaxis, response to interferon-gamma, iron ion homoeostasis, 
positive regulation of I-kappaB kinase (NF-kappaB signaling), rhythmic processes, 
and regulation of lipid metabolic process (Figure 9).   
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Figure 9.  Pathway analyses show upregulated lung specific genes in SCD 
mice. GO terms for the pathways are shown in the figure and the number of genes 
for each pathway identified is also indicated in the figure. P values <0.05 were set as 
cut off and were determined as significant compared to WT.  
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Although several pathways were upregulated in SCD mice, I became 
intrigued by series of genes involved in rhythmic processes, heme and iron 
homeostasis, and inflammatory response as shown in the heat map (Figure 10 ). 
The heat map contains expression of genes at a cut off score of P< 0.05 in SCD and 
WT samples.  Interestingly, several rhythmic process genes were upregulated at a 1 
to 2 fold change in SCD lung, include Basic helix loop helix family member e 40 
(Bhlhe40), D-box binding protein (Dbp), Period 2 (Per2), DNA-binding protein 
inhibitor 1 (Id1), DNA-binding protein inhibitor 2 (Id2), Nuclear receptor subfamily 1 
group D member 1 (Nr1d1), Nuclear receptor subfamily 1 group D member 2 
(Nr1d2), Thyrotroph embryonic factor (Tef), and Nicotinamide 
phosphoribosyltransferase (Nampt).  
Moreover, I identified that genes pertaining to heme and iron homeostasis, 
Lipocalin 2 (Lcn2), Ferrochelatase (Fech) ,Lactoferrin (Ltf), Solute carrier family 25, 
member 37 (Slc25a37), Metalloreductase 2 and 4 (Steap 2 and Steap 4)  were 
elevated in SCD lung (Figure 10).  Additionally, the screen revealed elevated 
inflammatory genes specific to SCD lung. These inflammatory genes were C-C motif 
chemokine ligand 5 (Ccl5), C-C motif chemokine ligand  17 (Ccl17), C-X-C motif 
chemokine ligand 2 (Cxcl2), C-X-C motif chemokine ligand 9 (Cxcl9), C-X-C motif 
chemokine ligand 10 (Cxcl10), C-X-C motif chemokine ligand 13 (Cxcl13), Interferon 
activated 202B (Ifi202b), Complement component 4 a (C4a), Complement 
component 4 b (C4b), Platelet factor 4 (Pf4), C-C chemokine receptor type 2 (Ccr2), 
C-C chemokine receptor type 4 (Ccr4), Nuclear factor, erythroid 2 like 2, (Nfe2l2), 
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Annexin a1 (Anxa 1), Prostaglandin g/h synthase 1 (Ptgs1), Toll-like receptor 6  
(Tlr6),  and A-disintegrin and metalloproteinase domain-containing protein 8  
(Adam8) (Figure 10).   
Using an unbiased approach, I demonstrated elevated expression of lung 
specific inflammatory, iron homeostasis, and rhythmic genes in SCD.  Induced gene 
expression of several heme and iron metabolic genes and inflammatory genes may 
provide intrinsic insight on the effect of intravascular hemolysis at the local tissue 
level.  
.    
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Figure 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
Figure 10. Unbiased microarray gene expression screen in SCD lung reveals 
upregulated expression of rhythmic clock genes, heme and iron hemostatic 
genes, and inflammatory genes. Heat map with bar plots correspond to gene 
expression was generated based on log2-tranformation. Gene fold changes was 
normalized to WT based on P<0.05 cut off score. Upregulated genes were indicated 
as red and downregulated genes were indicated as blue.  
 
 
3.2.2. Period 2 (Per2) induction in SCD lung underlines molecular clock function to 
deter further inflammatory response and tissue damage. 
Since I discovered an increase in the expression of rhythmic process genes, I 
determined whether these genes were further upregulated during a circadian cycle. 
The core circadian genes that regulates molecular clock function are Per1, Per2, 
Arnt, and Clock.  I discovered that Arnt gene in WT lung was expressed fold 2 to 3 
higher compared to SCD lung (Figure 11).  
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                        Figure 11 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  Circadian gene expression in SCD compared to WT lung.  Scatter 
plot of differentially expressed circadian rhythmic genes in SCD and control lung. 
Red dots show enriched genes in SCD whereas blue dots show elevated genes in 
WT lung. Circadian gene (s) Per2, Dbp, Id1, Nr1d1, and Nr1d2 were increased by 2 
in SCD whereas Arnt1 was increased by 1.5 in WT.   
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I determined whether Per2 and Arnt could be detected in SCD and WT lung  
at various time points during the day. To test this, I purified RNA from SCD and WT 
lung then I performed semiquantification RT-PCR  (qRT-PCR) to detect these 
circadian genes at environmental light and dark conditions, which corresponds to 12 
hours light and 12 hours dark also known as zeitgeber time (ZT). Tissue collection 
was performed as ZT: 1, 7, 13, 19, and 26. When I validated the mRNA expression 
of Per2 and Arnt; I found that Per2 gene expression was much higher in SCD lung 
compared to WT lung during a circadian cycle compared to previous results.  During 
ZT 1-13, Per2 gene expression change  2 to 3 fold, which increased to a fold change 
of 3 to 4 at ZT 19-26 (Figure 12B). Moreover, a phase change in Per2 was apparent 
in SCD lung. 
Figure 12 
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Figure 12.  Circadian Arnt (Bmal) and Per2 mRNA expression levels detected 
by semiquantitative real time polymerase chain reaction (qRT-PCR). Values 
represented as means ± SEM, * P<0.05, Fold change represented as SCD 
normalized to WT.  
 
 
Since elevated Per2 mRNA was seen in SCD mice, I confirmed whether 
PER2 protein levels mimic Per2 mRNA levels in SCD. To test this, I generated SCD 
→ Per2 Luciferase (SCD →Per2 Luc) mice and WT → Per2 Luciferase (WT → Per2 Luc) mice 
by means of adoptive SCD or WT bone marrow (BM ) cells transfer to lethally 
irradiated Per2Luc bioluminescent reporter mice (Figure 13 A) .  Per2 Luc transgenetic 
mice were created by the insertion of the luciferase reporter into the open reading 
frame (ORF) of the Per2 gene (42) . Heterozygous and mutant (Per2 Luc/+ and Per2 
Luc/Luc) mice were used as recipients for the BM transplantation studies. Further 
details on generation of these mice is found in the Methods Section of this 
dissertation. I utilized these mice for detecting PER2 luciferase oscillations in tissue 
cultures isolated from the mice (Figure 13 B). PER2 oscillations in tissue explants 
are robust even after tissues are removed from the animal (42). The PER2 
oscillations reflect a 24 hour cycle that can predict Per2 mRNA and PER2 protein 
expression based on the luciferase levels. Cultures were placed in a water jacketed 
CO2 incubator that is also light protective and equipped for recording PER2 
oscillations in real time (Figure 13 B). Terminology used to describe the PER2 
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oscillations: amplitude and period. Amplitude refers to the height of the PER2 peaks 
and the period refers to frequency of the PER2 peaks (Figure 13 B).   
Since I previously showed that Per2 mRNA levels were induced in the SCD 
lung, I isolated lung from SCD and WT transplanted mice to determine PER2 
luciferase activity in lung tissue cultures for up to 36.5 hours. The frequency of the 
PER2 peaks show no difference in the SCD → Per2 Luc or the WT → Per2 Luc mice. 
Moreover, I observed increase of luciferase expression based on the intensity of the 
PER2 peaks in lung cultures isolated from the SCD → Per2 Luc mice compared to 
control mice. Overall, these results imply that Per2 mRNA and PER2 protein levels 
are elevated in SCD mice compared to WT controls.  
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Figure 13. PER2 luciferase activity is higher in SCD. (A) Generation of Per2 Luc 
mice with SCD or WT phenotype. (B) Schematic of the work-flow for PER2 
oscillation recordings performed in tissue explant cultures. (C) Data analysis of 
luminescence detection in lung cultures. Values represents means ± SEM *P<0.05, 
SCD versus WT lung. N= 3 per group.  
 
 
3.2.3. Molecular clock dysfunction contributes to further tissue damage in SCD  
Since elevated Per2 levels were identified in SCD mice, I determined whether 
the increased Per2 in SCD plays a role in the disease.  Per1 and Per2 are 
homologous genes that are transcriptionally regulated by BMAL and CLOCK genes 
to promote molecular clock function in multiple organs.  The absence of Period 
genes disrupt circadian rhythms due to molecular clock dysfunction (30). To 
determine whether Period genes regulate molecular clocks in SCD, I generated SCD 
phenotypic Per1/Per2 double knock out (dKO) mice by BM transplantation. WT or 
SCD BM was transferred to irradiate WT or Per1/Per2 dKO mice (Figure 14 A).  As 
such four BM transplant groups, WT→ WT, WT→ Per1/Per2 dKO, SCD→ WT, and 
SCD→ Per1/Per2 dKO mice were generated. After 8 weeks post BM transplantation, 
peripheral blood was extracted to detect adoptive transfer of WT or SCD leukocytes 
using fluorescent CD45.1 or CD45.2 expression analyzed by flow cytometry. SCD 
phenotype mice express high chimerism of CD45.1 ~ 84 to 94 % (Table 4).  Control 
WT phenotype mice typically express high CD45.2 and no CD45.1.  
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Additionally, I analyzed multiple hematological parameters by performing 
CBC analyses on SCD and WT chimeric mice.  In SCD mice, the RBC counts range 
was ~ 5.80 to 5.97 x106 cells/ µl, HB range was ~7.55 to 7.83 g/dl, HCT range was 
~35.55 to 36.33 %, RDW range was ~35.33 to 36.33 %, MCV range was ~42.67 to 
45.85,  and reticulocytes (Ret) range was ~32.42  % (Table 4).  These values 
represent typical hematological parameters for sickle mice. In addition to CBC 
analysis, I examined the morphology of erythrocytes isolated from the SCD→ WT 
and SCD→ Per1/Per2 dKO mice to determine the sickling.  I quantified the sickling 
in SCD BM transplanted mice and observed similar sickling percentages ~13% in 
both SCD groups. Moreover, there were no significant differences between the WT 
or Per1/Per2 dKO mice with SCD phenotype.  In comparison to WT mice, RBC 
counts were ~ 10.94 x106 cells/ µl, HGB ~ 12.00 g/dl, HCT ~43 %, and Ret ~4 % 
(Table 4). Chimeric WT or Per1/Per2 dKO mice generated by BM transplantation 
showed typical hematological patterns for WT phenotype mice.  
Unexpectantly, I observed that white blood cells (WBCs) and neutrophils 
(NEs) were increased in SCD→ Per1/Per2 dKO mice. In the WT mice transplanted 
with SCD BM, WBCs were ~31 k/µl, and NEs were ~3.7 k/µl whereas Per1/Per2 
dKO mice with SCD phenotype, WBCs were ~ 50.47 k/µl and NEs were ~7.03 k/µl 
(Table 4).  In comparison to WT or Per1/Per2 dKO with WT phenotype, expressed 
normal ranges of WBCs ~ 3 k/µl and NEs~ 1 k/µl (Table 4). Although Per1/Per2 
does not play a role in sickling, I found that Per1/Per2 may play a significant role in 
immune cells in the periphery.  
 
62 
 
 
Table 4 
 
Table 4: Bone marrow transplantation of wild-type (WT) or sickle cell disease 
transgenetic (SCD Tg) bone marrow  to irradiated Per1/Per2 dKO or WT mice 
recipients; RBC: red blood cell count; HB: hemoglobin; HCT: hematocrit; RET: 
reticulocytes; WBC: white blood cells, and  NE: neutrophils. Confirmation of sickle 
cells by erythrocyte morphology detection methods and expression of positive 
CD45.1 leukocyte populations in chimeric sickle transplanted mice.*P < 0.05 versus 
WT→ WT; ** P<0.01 verses SCD→ WT; N=5-7. 
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Next, I determined whether the loss of Per1/Per2 plays a role in molecular 
clock dysfunction in multiple tissues.  To test this, I performed histological 
assessments to analyze tissue damage in lung, liver, and spleen.  By comparing 
histopathology of the SCD and WT transplant groups, I observed that SCD → 
Per1/Per2 dKO mice had worse lung damage due to increase infiltration of 
inflammatory cells leading to further lung congestion (Figure 14 B). Evidence of 
further lung damage was determined in SCD → Per1/Per2 dKO mice compared to 
SCD→ WT mice (Figure 14 B &C).   
In addition to the lung, there was evidence of damage occurring in the spleen 
and the liver. Sickle mice have elevated intravascular hemolysis due to chronic 
sickling with severe necrotic areas from chronic accumulation of heme and iron. In 
this case, I observed more necrosis in the sickle organs derived from Per1/Per2 dKO 
mice compared WT (Figure 14 B). No observation of liver or spleen necrosis in WT 
phenotypic mice was observed; but, necrotic regions in liver and spleen were 
evident in sickle phenotypic mice (Figure 14 D & E).  More apoptotic cells could be 
the reason as to why I observed more lung and liver damage in Per1/Per2 deficient 
sickle mice (Figure 14 B-D).   
 
 
 
 
 
 
 
64 
 
 
Figure 14 
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Figure 14.  Loss of Per1/Per2 contributes to multiple tissue damage in SCD.   
(A) Cartoon of BM transplant groups generated with WT or SCD phenotype. (B) 
Histopathological assessment of lung, liver, and spleen in BM transplant groups. (C-
E) Semiquantitative analysis of multiple tissue histological assessment. Values 
expressed as means ± SEM, *P<0.01, WT → WT or WT →Per1/Per2 dKO versus 
SCD → WT, **P<0.01, SCD → WT versus SCD → Per1/Per2 dKO.  N=5 to 6 mice 
per group.   
 
Severe histopathological outcomes were detected in sickle organs with 
Per1/Per2 genetic deletion. I asked whether Per1/Per2 dKO mice with SCD 
phenotype also had renal and hepatic dysfunction. To test hepatic function, I 
measured alanine aminotransferase (ALT) levels in serum isolated from transplant 
mice. ALT is an enzyme that converts glutamate and pyruvate in order to generate 
α-ketoglutarate and alanine. This mechanism is essential for liver metabolism. 
Although ALT is normally expressed in the liver, elevated ALT levels in the serum 
indicates hepatic dysfunction.  In my sickle mice, I observed an increase in serum 
ALT in SCD → Per1/Per2 dKO mice compared to SCD→ WT mice (Figure 15 A).  
This indicates that Per1/Per2 contributes to hepatic function in sickle mice. 
Moreover, I tested renal function by detection of albumin levels in the urine. Higher 
concentrations of albumin in the urine indicates renal dysfunction. Albumin 
concentrations were normalized to creatinine for each specimen tested.  In my 
analysis of renal function in the sickle mice, I observed higher albumin 
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concentrations in SCD → Per1/Per2 dKO mice, which indicates severe renal 
dysfunction (Figure 15 B). Normal renal function was observed in WT phenotype 
transplanted mice (Figure 15 B).  
 
Figure 15 
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Figure 15.  Hepatic and renal dysfunction in Per1/Per2 deficient sickle mice. (A)  
Analysis of ALT to determine hepatic function in transplant groups. (B) Renal 
dysfunction analysis confirmed by albumin concertation normalized to creatinine. 
Values expressed as means ± SEM, *P<0.01, WT → WT or WT →Per1/Per2 dKO 
versus SCD → WT, **P<0.01, SCD → WT versus SCD → Per1/Per2 dKO.  N=5 to 6 
mice per group.   
 
 
Unexpectantly, I observed increased irradiation sensitivity in Per1/Per2 dKO 
mice with SCD phenotype. Although all of the transplant mice were lethally 
irradiated, the SCD → Per1/Per2 dKO mice were more sensitive due to evidence of 
irradiation damage in the cranial and dorsal regions (Figure 16). No obvious 
irradiation damage was found in WT or Per1/Per2 dKO mice transplanted with WT 
BM was observed. Similarly, irradiation damage was not evident in WT mice 
transplanted with SCD BM. This indicates that peripheral Per1/Per2 has an overall 
protective role in sickle mice.  
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Figure 16 
 
 
 
 
 
 
 
 
 
Figure 16. Phenotypic observation of effect of whole body irradiation in transplant 
groups. Increased irradiation sensitivity in Per1/Per2 dKO mice with SCD phenotype. 
 
3.2.4. Systemic inflammation contributes to elevated lung neutrophil infiltration due 
to global genetic deletion of Per1/Per2 in sickle mice.  
Neutrophil adhesion to the lung vasculature contributes to endothelium 
dysfunction in SCD pathophysiology. Since an increase of neutrophils in the 
circulation was observed in SCD →Per1/Per2 dKO genetic deficient mice compared 
to the sickle→WT mice (Table 4), I determined whether peripheral Per1/Per2 was 
involved in regulating inflammatory responses in the lung. As indicated by 
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histological studies, I observed further lung congestion due to increased 
inflammatory infiltration in the lung. The majority of inflammatory cell types were BM-
derived, which can infiltrate to tissues from the periphery. Although mixed 
populations of BM-derived and resident cell types was found in multiple tissues 
isolated from Per1/Per2 dKO mice. The role of Per1/Per2 in multiple immune cell 
types and systemic inflammation in sickle lung is not fully understood.  
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Based on the CBC results (Table 4), I generated a hypothesis that Per1/Per2 
dKO sickle mice have elevated systemic inflammation, which contributes to further 
lung tissue damage. To test this, I isolated whole lung from mice transplanted with 
SCD or WT BM and performed immunohistochemistry to detect neutrophils  (Ly6-
neutrophil maker). In WT control mice, I detected no neutrophil infiltration to 
vasculature walls in the lungs (Figure 17 A &B). However, I observed more 
neutrophils in the sickle lungs as indicated by red arrows (Figure 17 A).  My original 
hypothesis is that neutrophil trafficking due to genetic deletion of Per1/Per2 were 
further enhanced in sickle lungs. I demonstrated this by detecting increased 
numbers of neutrophils  in sickle Per1/Per2 dKO lungs (Figure 17 B). Based on 
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these findings, I conclude that genetic deletion of Per1/Per2 in sickle mice 
contributes to more neutrophils in the lung tissue.  
 
Figure 17 
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Figure 17.  Loss of Per1/Per2 in SCD contribute to increased pulmonary 
neutrophil infiltration. (A) Immunohistochemistry images to show Ly6 neutrophil 
expression in WT→WT, WT → Per1/Per2 dKO, SCD →WT, and SCD → Per1/Per2 
dKO. Arrows identify presence of neutrophils in the lung vasculature. (B) Images 
were captured at a 20X objective for counting neutrophils per field. 5 or 6 slides were 
stained for Ly6 neutrophil marker in WT or SCD transplant groups. For WT →WT 
and WT → Per1/Per2 dKO, neutrophils were not detected (ND). *P<0.05, SCD → 
WT versus WT →WT or WT → Per1/Per2dKO; **P<0.05, SCD → WT versus SCD→ 
Per1/Per2dKO.  
 
 
 
3.2.5. Genetic deletion of Per1/Per2 in sickle mice is involved in tissue lung 
dysfunction as confirmed by further induction of inflammatory Toll-like receptor 4 
(Tlr4) and IL-6 gene expression as well as elevated IL-6 protein levels in 
bronchoalveolar lavage (BAL) fluid.   
 
In addition to elevated inflammatory cells in the periphery, the presence of 
neutrophils in the lung indicates that inflammation is further enhanced in Per1/Per2 
deficient sickle mice. To determine whether elevated inflammatory cells in the sickle 
lung contributes to upregulated inflammatory gene expression, I examined Tlr4 and 
IL-6 mRNA levels to determine whether genes are induced in sickle lung tissue. As 
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expected, I observed an upregulation of Tlr4 and IL-6 mRNA expression in sickle 
mice compared to control mice (Figure 18 A &B). In fact, I observed further induction 
of these inflammatory genes in SCD→ Per1/Per2 dKO mice compared to SCD→ 
WT mice, which indicates that genetic deletion of Per1/Per2 contributes to this 
induced inflammatory gene response.  
Since I observed further induced IL-6 mRNA expression in the lung, I 
validated plasma and systemic IL-6 protein levels in transplanted mice. I measured 
IL-6 protein levels in BAL fluid isolated extracted from lung, a common technique to 
diagnose lung damage in mice. In WT BM transplanted mice, I detected ~200 pg/mL 
of IL-6 protein levels in the lung fluid. In normal mice, this is an acceptable 
concentration (Figure 17 C). Moreover, in sickle mice, higher levels of IL-6 protein 
levels were detected, which indicates severe lung dysfunction. In SCD → WT lung, I 
detected even higher concentration of IL-6 protein levels at ~500 pg/mL (Figure 18 
C). In SCD →Per1/Per2 dKO lung, even more IL-6 were detected at ~650 pg/mL 
(Figure 18 C).  Taken  together, I conclude that elevated Tlr4 and IL-6 inflammatory 
gene expression and further increase of IL-6 protein levels indicate that genetic 
deletion of Per1/Per2 play a role in severe lung dysfunction in SCD mice.   
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Figure 18.  Analysis of Tlr4 and IL-6 inflammatory gene expression in lung 
tissue and IL-6 protein detection in BAL fluid. Values represent means ±SEM, 
*P<0.05, SCD → WT versus WT → WT or WT →   Per1/Per2dKO; **P<0.01, SCD 
→ WT versus SCD→ Per1/Per2dKO. 
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Since I generated sickle and WT mice with or without Per1/Per2 deficiency by 
bone marrow transplantation studies. I speculate that the increased of NEs are BM-
derived Per1+/+/Per2+/+ cells. However, the infiltration of neutrophils to the lung 
implies a mixed population of cells that are either Per1-/-/Per2-/- and Per1+/+/Per2+/+. I 
provide evidence of more lung and liver tissue damage in the sickle mice with 
Per1/Per2 deficiency. In addition to this finding, I observed more irradiation damage 
in sickle phenotypic mice with Per1/Per2 deficiency, which attributes the importance 
of Period genes in regulating cellular processes required for tissue function. With 
these observations, I speculate that Per1/Per2 play a role in regulating systemic 
inflammation, tissue damage, and dysfunction in SCD.  
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 Chapter 3: Elevated heme and iron levels in sickle mice is 
mediated by heme oxygenase 1 (HO-1)  
 
This chapter is based on unpublished work by Adebiyi MG, Zhao Z, Youqiong Y, 
Manalo J, Hong Y, Hill R, Gong J, D’Alessandro A, Lee CC, Xian W, McKeon F, 
Kellems RE, Yoo SH, Han L, and Xia Y. 
 
In this chapter, I will discuss more details as to why sickle mice with 
Per1/Per2 deficiency have more severe tissue damage. Since intravascular 
hemolysis is the cause of multiple tissue dysfunction, I will explore the role of an 
important enzyme heme oxygenase 1 (HO-1), which mediates heme degradation 
that contributes to iron release and trafficking to multiple  tissues.  
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3.3.1. Systemic hemolysis meditates heme and iron deposition in lung.  
Erythrocyte sickling is the hallmark of SCD. Hemolysis contributes to the 
release of heme, globin proteins, and iron in the periphery, which can traffic to 
multiple organs such as the liver. Elevated heme and iron in the organs can promote 
devastating effects due to increase toxicity that can result in multiple organ 
dysfunction. Particularly, iron can form dangerous compounds in the presence of 
reactive oxygen species (ROS), but the mechanism regarding elevated iron in the 
lungs is not fully understood. To determine whether pulmonary organ dysfunction in 
sickle mice is due to elevated levels of heme and iron deposition, I performed Perl’s 
Prussian blue iron immunohistochemistry studies to examine local iron content  in 
multiple organs isolated from transplanted mice with WT and SCD phenotype. As 
expected, I observed more iron in the spleen and liver vasculature in the sickle 
transplant mice, which indicates that sickling contributes to iron deposition to these 
organs (Figure 19 A). However,  in WT phenotypic transplant mice no increase in 
iron was observed (Figure 19 A).  
I discovered that Per1/Per2 deficient mice with sickle phenotype expressed 
more iron in the liver compared to other sickle phenotypic WT transplanted mice 
(Figure 19 A). I performed analyses to compare iron deposition in the sickle mouse 
spleen and liver. As revealed from my immunohistological studies, I observed more 
iron expression in sickle mouse liver with Per1/Per2 deficiency compared to the 
other sickle mouse group (Figure 19 B).  I did not observe obvious differences in iron 
levels to the sickle spleens in the WT or Per1/Per2 deficient sickle mice (Figure 19 
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C). As indicated in previous studies, spleen and liver are expected to have more iron 
since erythrocyte recycling mechanisms take place in these organs. Interestingly, I 
observed that iron levels can increase in the Per1/Per2 deficient sickle mouse lung 
and not in WT sickle mouse lung, which is unexpected (Figure 19 A).   
To determine whether elevated heme in the sickle mouse lung contributes to 
lung dysfunction, I performed biochemical analyses to detect heme levels in WT and 
sickle lung. As expected, I measured more heme in sickle lung than in the WT lung 
(Figure 19 D).  Interestingly, higher heme was detected in Per1/Per2 deficient sickle 
lungs compared to the WT sickle lungs, which indicates that elevated heme content 
in the lung is associated with the loss of  Per1/Per2 (Figure 19 D).    
Lastly, heme degradation contributes to generation of iron and bilirubin, 
products of heme metabolism. Since elevated heme and iron were detected in sickle 
mice, I measured serum levels of total bilirubin to determine whether chronic 
hemolysis mediates systemic production of bilirubin release from damaged 
erythrocytes. As expected, I observed that sickle mice had elevated bilirubin, which 
was further increased in Per1/Per2 deficient sickle mice (Figure 19 E). Based on 
these results, elevated heme, iron, and bilirubin is further induced in Per1/Per2 
deficient sickle mice, which indicates that these dangerous metabolic compounds 
play a role in multiple organ dysfunction in sickle mice.  
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Figure 19.  Heme, iron, and bilirubin are increased in sickle mice with 
Per1/Per2 deficiency.   (A) Perl’s Prussian blue iron immunohistochemistry staining 
of lung, liver, and spleen isolated from WT and SCD phenotypic mice with or without 
Per1/Per2 deficiency. (B-C) Semiquantification analyses of liver and spleen. (D) 
Biochemical detection of heme in the lung. (E) Total serum levels of bilirubin isolated 
from transplanted mice. Values represented as means ±SEM, *P<0.05, SCD → WT 
versus WT → WT or WT → Per1/Per2 dKO; **P<0.01, SCD → WT versus SCD→ 
Per1/Per2 dKO. ND means not detected.  
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3.3.2. Enhanced heme oxygenase 1 (HO-1) expression in macrophages is required 
for compensation due to elevated inflammation in SCD lung.  
Since systemic hemolysis is evident in sickle mice and contributes to induced 
heme, iron, and bilirubin levels, I determined whether heme oxygenase 1 (HO-1), 
which is the enzyme that mediates heme degradation. In sickle mice, HO-1 is widely 
expressed in multiple cell types including macrophages and endothelial cells, which 
mediate heme degradation. In fact, further induction of HO-1 is beneficial in SCD 
due to degradation of heme to generate metabolic products used for essential 
biological processes such as erythropoiesis.  
Although multiple cell types express HO-1 and surprisingly iron deposition 
was identified in the lung due to the loss of Per1/Per2 in sickle mice, I determined 
whether alveolar macrophages express HO-1. As previously shown, I observed iron 
content that was not widely observed in the Per1/Per2 deficient sickle mouse lung, 
therefore, I tested whether alveolar macrophages expressed HO-1 to contribute to 
iron deposition in the lung. To test this, I isolated WT and SCD mouse lung with or 
without Per1/Per2 and performed immunohistochemistry studies. Interestingly, I 
observed wide distribution of HO-1 expression in sickle mice compared to control 
mice, which is likely due intravascular sickling events in the organ (Figure 20).  In 
fact, I observed a specific lung vasculature region that distinctly contain HO-1 
positive cell types in Per1/Per2 deficient sickle mice, which confirms that HO-1 
mediates heme and iron deposition in these cells (Figure 20). To determine whether 
macrophages express HO-1, I co-stained lung sections with F4/80, which is a 
specific macrophage marker. In sickle mice, I observed more F4/80+ cells in the 
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sickle lung, but,  I did not observe significant differences in F4/80+ expression in WT 
transplanted mice (Figure 20).  Overall, I have observed more HO-1 in lung 
macrophages  in Per1/Per2 deficient sickle mice.  
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Figure 20. Immunohistochemistry studies reveal HO-1 expression in peripheral 
lung macrophages. Blue panel show DAPI staining of cellular nuclei, red panel 
show HO-1, and green panel show F4/80.  
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Illustration 3. Summary of unpublished results for chapter 2 and chapter 3. Overall, 
elevated Per2 was identified in SCD tissue and has robust circadian rhythmic 
expression in SCD lung. Additionally, I discovered that when Per1/Per2 is taken 
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away this causes further IL-6 levels, iron overload, and further multiple organ 
damage in SCD.   
 
Systemic hemolysis in SCD contributes to iron and heme deposition in 
multiple organs. I provide evidence that Per1/Per2 gene deletion in sickle mice 
contributes to further heme and iron in multiple organs. Elevated heme and iron can 
be toxic if not used efficiently for biological processes or if too much heme and iron 
disrupts overall organ functioning. Based on previous results, I demonstrated that 
Per1/Per2 gene deletion contributes to further hepatic dysfunction in sickle mice 
(Chapter 2).  Altered liver metabolism due to increased heme and iron led to further 
hepatic dysfunction. In the lung, neutrophil infiltration and elevated inflammatory 
gene expression contribute to tissue damage. Unexpectantly, I discovered elevated 
levels of iron deposition in the SCD phenotypic Per1/Per2 deficient lung, which led 
me to determine whether macrophages either Per1+/+/Per2 +/+ or Per1-/-/Per2-/- 
contributed to iron deposition in the lung. As revealed by my immunohistochemistry 
studies, I showed that alveolar macrophages in sickle Per1/Per2 dKO mice were 
also positive for HO-1, which is the enzyme that mediates heme and iron 
degradation in macrophages. Taken together, I have identified a potential target in 
macrophages that regulates heme and iron metabolism to promote heme and iron 
deposition.  
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IV. Discussion  
 
4.1. Summary of dissertation chapters. 
Since elevated SphK1-S1P mediates sickling, hemolysis, and multiple organ 
damage in SCD.  My work addressed how S1P signaling underlines SCD 
progression.  In chapter 1, I discussed how elevated SphK1-S1P production 
upregulates S1PR1, which can be targeted by FDA-approved drug FTY720. 
Although targeting S1PR1 does not affect erythrocyte sickling, I discovered that 
elevated S1PR1 and IL-6 is regulated in a JAK2-dependent manner, which 
contributes to further multiple tissue damage, systemic inflammation, and tissue 
dysfunction in SCD.  Since multiple organ damage is a severe consequence of SCD 
patient morbidity and mortality, the mechanism that underlies organ damage is not 
fully understood. To explore these potential mechanisms, I performed a high 
throughput unbiased screen, which revealed a series of genes in inflammatory 
response, heme and iron metabolism, and circadian rhythmic genes.  In addition to 
circadian clock function, Per1/Per2 genes play a role in organ and cellular function.  
Therefore, in chapter 2, I discuss how the loss of Per1/Per2 in SCD contributes to 
elevated IL-6 to promote systemic inflammation and multiple tissue damage. 
Furthermore, Per1/Per2 play a role in heme metabolism. Elevated heme and iron 
level deposition in SCD can promote organ toxicity. In chapter 3, I discussed how 
the loss of Per1/Per2 in SCD contributes to elevated heme deposition in SCD tissue. 
Due to increase heme content, this can lead to upregulated HO-1 activity, which is 
required for compensation.   
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Illustration 4 
 
 
Illustration 4: Summary of dissertation chapters 1-3. In chapter 1, I have identified 
that elevated S1P-S1PR1 contributes to increase IL-6, which promotes systemic 
inflammation, multiple tissue damage, and tissue dysfunction. In chapter 2, I 
discovered that the loss of Per1/Per2 in SCD contributes to increase IL-6, which 
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contributes to an increase of multiple tissue damage, systemic inflammation, and 
tissue dysfunction. In chapter 3, I demonstrated that the loss of Per1/Per2 in SCD 
mediates increase heme and iron deposition in multiple organs, which further 
increases HO-1 activity for compensation.  
 
4.2. Overview of circadian clocks mediating physiological processes in normal and 
disease conditions. 
The circadian clock can regulate physiological processes, such as 
cardiovascular activity, immunity, hormonal secretion, energy metabolism, and 
behavior (56-58). Disturbances alter the circadian clock and obstruct multiple 
processes that are not genetically adaptable and are detrimental (59, 60). Circadian 
clock synchronizers function to maintain self-sustaining circadian gene oscillation 
patterns (33). The peripheral clocks are regulated in a diurnal manner, which are not 
necessarily dependent on environmental light cues (61). Peripheral clocks function 
independently from the core central clock in the suprachiasmatic nuclei (SCN) 
located in the hypothalamus. Cells in the SCN are primarily synchronized by external 
light (62). Multiple cell types in peripheral tissues also orchestrate self-sustaining 
circadian rhythms that can persist independently of environmental cues, i.e. light 
(63). Depending on the physiological processes, energy metabolism can be 
regulated by biological clocks in peripheral organs, such as the pancreas, adrenal 
glands, and the liver (62). Food consumption is regulated by the circadian clock and 
functions as a metabolic signal to synchronize rhythms in the liver, but, not in SCN 
(63, 64). Circadian disturbances and other circadian cycle manipulations, such as 
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excess light or dim light can restrict feeding, which can obstruct metabolic signals 
that contribute to disease (65, 66). However, independent of light and metabolic 
influences, cancer, cardiovascular diseases, and diabetes can result due to 
endogenous circadian clock defects that promote disease progression (23, 56, 57, 
67).  
 
4.3. Heme is a circadian clock regulator.  
Metabolites function as signals that regulate circadian clock function (57). 
These metabolites include heme, glucocorticoids, lipids, insulin, carbohydrates, 
amino acids, and fatty acids that can function as central and peripheral clock 
synchronizers (68). For example, glucocorticoids, the steroid hormones, are 
released from the adrenal glands, but, are regulated by the central clock in the SCN 
(69). Glucocorticoids are essential for synchronizing rhythms in peripheral organs 
and have functions in mediating inflammatory responses that contribute to disease 
(57, 70). Heme is released from erythrocytes and functions to regulate oxygen 
transport and other biochemical processes. Excess of heme or other metabolites 
can obstruct proper clock function, which is detrimental (71-73). The biochemical 
structure of heme contains unique per-arnt-sim (PAS) regions, which function to 
facilitate ligand binding to receptor, which can mediate signal transduction pathways 
(74). These heme-PAS domains are ubiquitously expressed including archaea and 
higher complex eukaryotic species, and have a variety of functions depending on the 
species (74). Heme-PAS complex can also facilitate transcription of circadian genes 
such as Per2, Npas2, Nr1d1, and Nr1d2 (31, 75, 76). 
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 Heme binding to neuronal Per-Arnt-Sim motif 2 (nPAS2) facilitates BMAL1-
NPAS2 complex binding to carbon monoxide (CO) sensitive regions on DNA (77). 
CO suppresses BMAL-NPAS2 binding to promoter regions thus inhibiting 
transcription of circadian genes, like Per1/Per2. Moreover, HO-1 is expressed in a 
variety of cell types including endothelial and myeloid cells, which function to restore 
circadian rhythms during tissue injury. In fact, myeloid cells expressing HO-1 confer 
protection in the brains of subarachnoid hemorrhage (SAH) mice models by 
suppressing apoptosis (78, 79). It has been demonstrated by pharmacologic 
inhibition and genetic models that hindering HO-1 activity can alter proper clock 
function in Drosophila and mice (77). When CO production is suppressed this can 
upregulate BMAL-NPAS2 complex promoting clock gene transcription that can 
contribute to abnormal glucose metabolism in mouse liver (77). Since complete 
darkness can function as a metabolic signal in mice (59), a microarray analysis was 
performed to demonstrate that light pulses in mice kept in darkness can regulate 
heme and iron metabolic related genes (80). In fact, light exposure functions as a 
stressor to induce heme oxygenase 2 (HO-2), a homologue to heme oxygenase 1 
(HO-1) (80). Other genes discovered from the screen were:  Stearoyl‐coenzyme A 
desaturase 1 (SCD1), Ferritin heavy and light chain 1 (FTH and FTL1), Matrix 
metalloproteinase 11 (MMP11), and Metallothionein1 (MT1) (80). Other detrimental 
contributions of elevated iron in the tissue includes oxidative stress due to iron 
oxidation from ferrous to ferric states. Elevated iron increases AMP-activated protein 
kinase (AMPK) activity thus affecting insulin and glucose signaling in mice (81).   
4.4. Pharmacologic induction of heme oxygenase (HO-1) for treating SCD. 
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Hemin, a ferric protoporphyrin chloride that is a derivative of heme, can alter 
circadian clock function by obstructing heme transcriptional modulation in cells. 
Further studies have demonstrated that hemin can be deleterious in cells and mice 
due to cellular toxicity that affects metabolic functions and pulmonary vaso-occlusive 
events (72, 73, 82). The mechanism involved requires heme oxygenase-1 (HO-1), 
which can be induced by heme or hemin. HO-1 is an enzyme that catabolizes heme 
to generate CO, iron, and bilirubin, which are products of heme degradation 
(Illustration 5).  
 
 
 
 
 
 
 
 
 
 
 
 
Illustration 5. Mechanism of heme degradation pathway. 
Illustration 5   
Hemolysis   
Heme- iron  
Heme-
Bilirubin 
SCD 
Carbon Iron  Biliverdin Carbon 
monoxid
e olysis  
Heme bound iron  
Heme oxyg nase 1   
92 
 
 
Further induction of HO-1-mediating heme degradation is beneficial in SCD. 
Due to elevated heme content in sickle cell organs, further HO-1 induction is 
necessary in order to compensate for excess heme, which contributes to vascular 
inflammation in SCD (83). In SCD, potential therapeutics involving inhaled CO and 
NO gases to improve vasodilation induce HO-1 expression thus inhibiting stasis in 
SCD mice. Notably, CO production mediated by HO-1 activity has potent anti-
inflammatory and anti-oxidative effects in the vasculature (84). In fact, previous 
reports have implied that a PEGylated form of hemoglobin saturated with CO gas 
recognized as MP4CO reduced hypoxia and hemin-induced stasis in SCD mice (85). 
HO-1 induction mediates nuclear erythroid factor 2 (Nrf2), which is a 
transcription factor that regulates HO-1 and other anti-oxidative genes (86). In my 
study, I discovered that the loss of Per1/Per2 plays a role in elevated heme and iron 
deposition in sickle mice, which contributes to further multiple organ damage. I 
determined whether HO-1 mediates heme and iron degradation in my sickle mice 
and found that increase of HO-1 expression in Per1/Per2 deficient sickle mice plays 
a role in heme and iron deposition in these mice. Thus, I speculate that systemic 
hemolysis in SCD contributes to release of hemoglobin: haptoglobin (HB:HP) 
complexes to the circulation. On cellular surfaces of multiple cell types, such as 
macrophages, contains a CD163, a scavenger hemoglobin receptor, which 
endocytosis HB:HP complexes from the circulation (87, 88). HB:HP and CD163 
receptor gets endocytosed by lysosomes for degradation. Moreover, heme bound 
iron and globin proteins get released from the lysosomes and HO-1 mediates the 
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degradation of heme in the cytoplasm. Heme can bind to heme receptors such as 
BACH 1 or 2 and REV-ERα or REV-ERβ located on the nuclear membrane (75). 
Heme-binding to heme receptors can induce transcription of Per2 (31). Since iron is 
released from heme bounded to iron, iron in ferric or ferrous form can be transported 
within the cell. Elevated iron deposition in organs can be detrimental due to 
inefficient iron recycling thus causing iron overload as demonstrated in my work. 
Although, the mechanism that contributes to Period genes expression in SCD is still 
unclear, I hypothesize that elevated heme mediate Per2 gene expression has a 
beneficial role in SCD (Illustration 6).  
                       Illustration 6 
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Illustration 6. Possible mechanism involving scavenger CD163 macrophage 
receptor mediating heme bound iron binding to heme receptors on nuclei to promote 
Per2 transcription.  
 
 
Additionally, dimethyl furmate, an agonist for Nrf2 signaling activation, can 
stimulate a HO-1 response to combat excess heme content in SCD organs (84). 
One of the functions of dimethyl furmate is to increase fetal hemoglobin (HbF), which 
reduces HbS polymerization. The chronic administration of dimethyl furmate in SCD 
mice reduces toxic heme accumulation in local tissues thus reducing  heme-
mediated inflammatory responses (89). Elevated of HbF in SCD and β-thalassemia 
can contribute to overall improved conditions in disease (90). In recent years, 
evidence has indicated that BCL11A protein is a repressor for HbF expression that 
contributes to elevated HbS polymerization, which mediates hemolytic anemia and 
end organ damage (91). BCL11A is a transcription factor that is required for B-cell 
development and expressed in mature erythroid cells (90, 91). In SCD, genetically 
targeting BCL11A lead to overall improvement in SCD phenotype (91).  
 
4.5. Macrophages induction of HO-1 contribute to iron overload in SCD.  
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Altered metabolic signals are directly related to molecular clock dysfunction 
that contribute to cardiovascular, behavioral, endocrine, and immune diseases (10, 
11), elevated inflammation in an immune cell dependent manner can result in 
dampening circadian rhythms that directly affect clock function in diseases such as 
COPD and inflammatory rheumatoid arthritis (70, 92, 93). In experimental 
inflammatory conditions, LPS-mediated inflammatory responses can trigger Per2 
gene expression in peripheral blood mononuclear cells (22, 94-96).  Additionally, 
natural killer cells, neutrophils, and macrophages have functional clocks that can be 
regulated by glucocorticoids and other metabolic signals (39, 97-101). In fact, 
infiltrating macrophages upregulate transcription of Per1, Per2, and N1rd1 circadian 
gene expression, which can promote inflammatory responses that contribute to 
tissue destruction (12-14).  Although altered metabolic signals in immune cells are 
directly related to molecular clock dysfunction, this can contribute to abnormal 
secretion of interleukin 6 (IL-6), tumor necrosis factor alpha (TNFα), chemokine- (C-
C motif) ligand 2 (CCL2), interferon gamma (INFy), prostaglandins E2 (PGE2), and 
toll-like receptor 9 (TLR9) signaling in macrophages (36, 102-106).  
Additionally, macrophages express HO-1, to support a variety of physiological 
processes that involve heme detoxification and iron recycling required for 
erythropoiesis. Hemoglobin-haptoglobin (HB-HP) is a complex that induces HO-1 
activity in macrophages (87). CD163 is a scavenger receptor expressed on 
macrophages, which facilitates the uptake of HB-HP complexes via an endocytosis-
dependent manner (88, 107, 108). Moreover, heme released from hemoglobin can 
mediate HO-1 induction in macrophages by upregulating ferroportin (FPN), an iron 
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transport, to regulate iron metabolism (109). In addition, elevated expression of 
ferritin, an iron storage protein is mediated by CD163 receptor, which is beneficial for 
combating iron overload (110).  
HO-1 induction in macrophages can have beneficial roles in disease. Excess 
iron is toxic to the cell due to generation of ROS mediated by Fenton and Harber 
Weiss reactions that can promote DNA damage, lipid peroxidation, and cross-linking 
of proteins (111, 112). Furthermore, elevated heme can mediate TLR4 signaling, 
which can induce the expression of inflammatory cytokines like IL-6 and TNF-α in 
SCD mice (113, 114).   
Sickle mice with biological clock dysfunction have a mixed population of cell 
types. BM-derived cells that are Per1+/+/Per2+/+ whereas the peripheral cells in 
resident tissues are Per1-/-/Per2-/- . With this possibility, macrophages expressing 
HO-1 has a mixed morphology, which may have diverse roles in disease such as M1 
or M2 macrophages, which have pro-inflammatory or anti-inflammatory functions in 
disease (Illustration 7). Taken together, I conclude that elevated HO-1 in 
macrophages contributes to heme and iron deposition to promote multiple organ 
dysfunction in sickle mice (Illustration 7).  
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Illustration 7. Mixed cell populations that are BM-derived Per1+/+/Per2-/- and resident 
Per1-/-/Per2-/- express HO-1, which regulates heme degradation in macrophages. 
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4.6. Elevated adenosine-mediate ADORA2B activation to promote Per2 induction, 
which improves disease severity. 
Circadian dysfunction contributes to metabolic defects that can promote 
energy imbalance in the animal (115). In SCD, metabolic changes in the 
erythrocytes contribute to poor oxygen release and further sickling (13, 116, 117). 
Metabolite precursors such as adenosine can facilitate 2,3-DPG induction, an 
allosteric modulator, that prompts oxygen release from hemoglobin (13). Adenosine 
is derived from adenosine triphosphate (ATP), a nucleoside with three triphosphate 
groups that regulates energy metabolism. Elevated extracellular adenosine signals 
via four G-protein coupled receptors that are ubiquitously expressed in a variety of 
cell types, including epithelial cells, immune cells, and erythrocytes (41). Amongst 
the four G-protein coupled receptors, ADORA2B has the lowest affinity for 
adenosine, which is activated due to excess accumulation of extracellular 
adenosine. In the erythrocytes, elevated adenosine mediated activation of  
ADORA2B receptor facilitates glycolytic pathways that function in oxygen release. 
Adenosine signaling via ADORA2B activation has known beneficial roles in hypoxia 
adaptation under normal conditions (118, 119). However, in inflammatory pulmonary 
disease and in SCD, elevated adenosine-mediated ADORA2B activation is 
detrimental and contributes to further disease progression (13, 118, 120). In fact, 
elevated adenosine mediated ADORA2B activation contributes to further PER2 
induction in cardiomyocytes. Further PER2 induction is regulated by upstream 
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enhancer elements that promote transcription of hypoxia-related genes, such as 
hypoxia inducible factor alpha (Hif1α) during hypoxic events (121).  
Hypoxia is a dangerous condition, in which, systemic deprivation of oxygen 
can result in inflammatory responses and end organ damage (122, 123). HIF 
subunits HIF1α and HIF1β (also known as BMAL), are key components of hypoxia 
signaling. Hypoxia can drive glycolytic processes and further contribute to metabolic 
disease (124). PER2 induction mediated by ADORA2B signaling can regulate 
glycolytic processes in a HIF1α dependent manner during ischemic-reperfusion 
injury (25). Glucocorticoids can mediate PER2 induction to promote clock function 
(92). In SCD, chronic hypoxia occurs due to systemic oxygen release from 
hemoglobin S (HbS) mediating sickling (17). In fact, further sickling is regulated by 
sphingosine kinase 1 (SphK1) in erythrocytes regulated in an adenosine-ADORA2B 
dependent manner (14). Due to oxygen release events, deoxy-hemoglobin S 
(deoxy-HbS) forms insoluble polymers that results in enhanced polymerization to 
promote vaso-occlusion and tissue damage in SCD (117). In the normal setting, 
SphK1-mediate S1P production contributes to 2, 3-DPG induction in erythrocytes, 
which plays a role in hypoxia adaptation in individuals at high-altitude (125). In SCD, 
elevated SphK1-S1P production in erythrocytes mediates sickling and end organ 
damage (14). Overall, the role of hypoxia contributing to further sickling is known; 
however, it is still uncertain whether hypoxia-mediate HIF1α is regulated by further 
PER2 induction in the periphery to promote SCD progression.  
4.7. Evidence of oxidative-reductive stress in sickle lung tissue. 
100 
 
Hypoxia plays a role in the pathophysiological impact of oxidative stress (119, 
120), collagen formation (121, 122), mitochondria dysfunction (123), and 
inflammation (124) in the lung. Hypoxia mediates erythrocyte sickling and further 
progression of SCD; however, the role of induced erythrocyte sickling and 
subsequently heme and iron trafficking to organs remains unclear. As a part of my 
dissertation studies, I determined whether molecular clock dysfunction mediated by 
the loss of Per1/Per2 in sickle mice plays a role in lung dysfunction. I have 
preliminary evidence that indicates that oxidative-reductive process genes are 
differentially expressed in the sickle lung with Per1/Per2 deficiency. These results 
were generated by an unbiased mRNA sequencing of lung tissue isolated from SCD 
or WT phenotypic mice with or without Per1/Per2. Amongst these RNA transcripts 
detected in sickle lung were: Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 
(Plod1), Malic enzyme 3, NADP (+)-dependent mitochondrial (Me3), Apoptosis 
inducing factor, (mitochondria associated 2) (Aifm2), Malate dehydrogenase 2, NAD 
(mitochondrial) (Mdh2), NADPH oxidase 1 (Nox1), Lysyl oxidase-like 4 (Loxl4), and 
Deiodinase, iodothyronine, type I (Dio1) (Illustration 8A). Upregulated mRNA levels 
were Plod1, Me3, Aifm2, and Mdh2 in Per1/Per2 deficient sickle mouse lung 
(Illustration 8A).  
Further, I also identified several genes that were upregulated in Per1/Per2 
deficient transplant mouse lung compared to WT transplanted lung.  WT → 
Per1/Per2 dKO lungs were normalized WT→ WT lungs. Amongst the transcripts 
detected were Prolyl 4-hydroxylase subunit alpha 3 (P4ha3), Biliverdin reductase A 
(Blvra), Peptidylglycine alpha-amidating monooxygenase (Pam), Dihydrouridine 
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synthase 3 like (Dus3l), Acyl-CoA dehydrogenase family member 8 (Acad8), 
Methionine sulfoxide reductase B2 (Msrb2), Delta(4)-desaturase, sphingolipid 1 
(Degs1), Cytochrome P450 family 1 subfamily A member 1 (Cyp1a1) , 
Protoporphyrinogen oxidase (Ppox), malic enzyme 1, NADP(+)-dependent (Me1), 
Cytochrome P450, family 26, subfamily b, polypeptide 1 (Cyp26b1), D-2-
hydroxyglutarate dehydrogenase (D2hgdh), Acyl-Coenzyme A oxidase-like (Acoxl), 
Scavenger receptor CD163 (Cd163), and Interferon activated gene 202B (Ifi202b) 
(Illustration 8B).  Interestingly, upregulated mRNA expression of P4ha3, Blvra, Pam, 
Cd163 and Ifi202b, was identified in WT→ Per1/Per2 dKO mice (Illustration 8B).  
Specifically, Blvra and CD163 have roles in regulating heme-iron metabolism (20, 
126).  
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Illustration 8. Differential expression of oxidative-reductive genes identified in 
mRNA sequencing of the lung isolated from SCD or WT BM transplant mice with or 
without Per1/Per2. P<0.05 cut off score was used to determine significance of 
genes. Upregulated genes were indicated as red and downregulated genes were 
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indicated as blue. Analyses revealed differential gene expression in SCD →WT 
compared to SCD → Per1/ Per2 dKO or WT → WT or WT→ Per1/Per2 dKO mice.  
 
4.8. Future directions.  
Oxidative stress, reactive oxidative species, and reduced anti-oxidative 
responses in SCD can be a regulated by Per 2. Future directions include performing 
metabolomics arrays to identify molecular clock functions at the cellular level in my 
WT and SCD transplanted mice. Since I transplanted SCD or WT bone marrow (BM) 
to irradiated Per1/Per2 dKO mice, it is likely that heterogeneous populations of cell 
types exist in the SCD and WT BM transplant mice due to Per1/Per2 positive BM-
derived cells that are expressed in the periphery. BM cells can differentiate to 
myeloid, lymphoid, and erythroid progenitor cell lineages that would be Per1/Per2 
positive. These circulating cells can then infiltrate multiple organs causing mixed 
populations of cells. Since a function of molecular clocks is to regulate metabolism, it 
would be important to explore metabolic pathways in our SCD and WT BM 
transplant mice. 
 Peripheral clocks regulate oxidative stress pathways to promote glutathione 
(GSH) synthesis and other anti-oxidative responses in Drosophila and mammalians 
(127, 128). GSH is a potent anti-oxidant that is circadian regulated. In Drosophila, 
GSH is circadian regulated in WT files, but, abolished in Per mutant flies (127). Thus 
it will be important to determine whether sickle Per1/Per2 dKO mice have abnormal 
metabolic lung profile compare to sickle BM transplanted to WT mice.  
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At the cellular level, erythrocytes, fibroblasts, immune cells, and liver cells 
express circadian patterns of anti-oxidant proteins such as peroxiredoxins, which are 
essential for combating ROS (50, 51). As part of my future studies, I will like to 
conduct single cell metabolomics by purifying macrophages from peripheral tissues 
and BM cells isolated from sickle BM transplant mice groups. I am interested to 
investigate whether elevated presence of ROS in Per1/Per2 dKO– sickle BM 
transplant mice results in unique changes in their metabolic profile from BM-derived 
cells compared to tissue macrophages.  
Lastly, heme and iron overload is a serious debilitating condition that can 
occur due to chronic transfusions in patients with severe hemolytic anemia such as 
SCD and β-thalassemia. There are two FDA-approved drugs, deferoxamine and 
deferasirox, which are iron chelators used in the clinic to treat iron overload. Since 
transplant SCD BM mice express excess iron in peripheral organs, future 
investigations could be to determine whether these pharmacologic tools can be 
beneficial for reducing iron levels in Per1/Per2 dKO sickle mice.  
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2015            American Society of Hematology Minority Abstract Achievement Award 
 
2012 to 2013            NIH- Post-Baccalaureate Enrichment Research (PREP) Scholar 
 
2009 to 2012           Spelman College Dean’s List 
 
2010 to 2012          Spelman STEM Scholar S3 
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2009 to 2012      United Health Diverse Initiative Scholar  
2011 to 2012      United Parcel Service Community Service Scholar  
2009 to 2010     Siemens Science Teacher Scholar 
2009 to 2010         Thurgood Marshall Scholar  
2010                Spelman College Research Day 1st Place Poster Presentation  
 
PUBLICATIONS 
 
Zhao S* and Adebiyi M.G.*,  Zhang Y, Couturier J, Fan X, Zhang H, Kellems R.E., Lewis 
D.E. and Xia Y. Sphingosine-1-phosphate receptor 1 mediates elevated IL-6 signaling to 
promote chronic inflammation and multi-tissue damage in sickle cell disease. FASEB J. 
2017. In press. [* First authorship shared] 
 
Sun K, D'Alessandro A, Ahmed M.H., Zhang Y, Song A, Ko T.P., Nemkov T, Reisz J.A., Wu 
H, Adebiyi M, Peng Z, Gong J, Liu H, Huang A, Wen Y.E., Wen A.Q., Berka V, Bogdanov 
M.V., Abdulmalik O, Han L, Tsai A.L., Idowu M, Juneja H.S., Kellems R.E., Dowhan W, 
Hansen KC, Safo M.K., Xia Y. Structural and Functional Insight of Sphingosine 1-
Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. Sci Rep. 
2017 Nov 10;7 (1):15281. 
 
Wu H, Bogdanov M, Zhang Y, Sun K, Zhao S, Song A, Luo R, Parchim N.F., Liu H, Huang 
A, Adebiyi M.G., Jin J, Alexander D.C., Milburn M.V., Idowu M, Juneja H.S., Kellems R.E., 
Dowhan W, Xia Y. Hypoxia-mediated impaired erythrocyte Lands' Cycle is pathogenic for 
sickle cell disease. Sci Rep. 2016 Jul 20;6:29637. 
 
Hu X, Adebiyi M.G., Luo J, Sun K, Le T-T.L., Zhang Y, Wu H, Zhao S, Karmouty-Quintana 
H, Liu H, Huang A, Wen Y.E., Zaika O.L., Mamenko M, Pochynyuk O.M., Kellems R.E., 
Etslzchig H.K., Blackburn M.R., Walters E.T., Huang D, Hu H and Xia Y. Sustained elevation 
of adenosine-ADORA2B signaling promotes chronic pain through neuro-immune interaction. 
Cell Rep. 2016 Jun 28; 16(1):106-19. 
 
Sun K, Zhang Y, D’Alessandro D, Nemkov T, Song A, Wu H, Liu H,  Adebiyi M, Huang A, 
Wen Y.E., Bogdanov M.V., Vila A, O’Brien J, Kellems R.E., Dowhan W, Subudhi A.W., 
Jameson-Van Houten S, Julian C.G., Lovering A.T., Safo M, Hansen K, Roach R.C. and Xia 
Y. Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for 
adaptation to high-altitude hypoxia. Nat Commun.2016; 7:12086. 
 
Ayalew M, Matheson K, Adebiyi M, Robinson S, Elston B. RNA-seq analysis of the effect of 
kanamycin and the ABC transporter AtWBC19 on Arabidopsis thaliana seedlings reveals 
changes in metal content. PLoS One. 2014 Oct 13; 9(10):e109310. 
 
Dharmasiri U, Njoroge S.K., Witek M.A., Adebiyi M.G., Kamande J.W., Hupert M.L.,  
Barany F and Soper S.A. High-Throughput Selection, Enumeration, Electrokinetic 
Manipulation, and Molecular Profiling of Low-Abundance Circulating Tumor Cells Using a 
Microfluidic System. Anal Chem. 2011 Mar 15; 83 (6):2301-9. 
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CONFERENCE PRESENTATIONS 
 
Adebiyi M.G., Zhang Y, Manlo J, Zhao Z, Lee C-C. and Xia Y. The role of circadian clock 
genes Period1/ 2 in Sickle Cell Disease. Biochemistry and Molecular Biology Annual 
Retreat, Magnolia, TX, March, 2017 
 
Adebiyi M.G., Sun K, Zhang Y, Hu X and Xia Y. The role and mechanism of Sphingosine-1-
Phosphate (S1P) signaling via S1P receptor 1 (S1PR1) in macrophage contributes to pain. 
American Society of Hematology, San Diego, CA, Dec, 2016 
 
Adebiyi M.G., Sun K, Zhang Y, Hu X and Xia Y. The role and mechanism of Sphingosine-1-
Phosphate (S1P) signaling via S1P receptor 1 (S1PR1) in macrophage contributes to pain. 
Graduate School of Biomedical Science at UTHealth/MD Anderson Research Day, Houston, 
TX, June, 2016.  
 
Adebiyi M.G., Utilizing rodent models to study chronic pain. Oral presentation delivered for 
UT-GSBS Summer Research Undergraduate Program (SURP), Houston, TX, June 2016.  
 
Adebiyi M.G., Sun K, Zhang Y, Hu X and Xia Y. The role and mechanism of Sphingosine-1-
Phosphate (S1P) signaling via S1P Receptor 1 (S1PR1) contributes to pain in Sickle Cell 
Disease. Oral presentation delivered at Society of Chinese Bioscientists in America meeting, 
Houston, TX, May 2016.  
Adebiyi M.G. and Xia Y. Studying the role of macrophages in models of inflammatory pain. 
Oral presentation delivered at seminar series titled, ‘I Dream of Flow Cytometry’, Houston, 
TX, January, 2016.  
 
Adebiyi M.G., Sun K, Zhang Y, Hu X and Xia Y. The role and mechanism of Sphingosine-1-
Phosphate (S1P) signaling via S1P Receptor 1 (S1PR1) in macrophage mediates 
inflammatory pain in Sickle Cell Disease. Oral presentation delivered at Translational Pain 
Research Symposium meeting, Houston, TX, April 2016 
 
Adebiyi M.G., Hu X, Luo J, Sun K, Le T-T.T., Zhang Y, Wu H, Zhao S, Liu H, Huang A, 
Kellems R.E., Etslzchig H.K., Blackburn M.R., Walters E.T., Hu H and Xia Y. Sustained 
elevation of adenosine-ADORA2B signaling promotes chronic pain through neuro-immune 
interaction in Sickle Cell Disease. Poster presentation delivered at American Society of 
Hematology, Orlando, FL,  December, 2015.  
 
Adebiyi M.G. and Ayalew M. The effect of the Arabidopsis ABC transporter Atwbc19 on 
transcript levels of iron regulated genes. Poster presentation delivered at Southern Regional 
Conference American Society of Plant Biology Conference, Myrtle Beach, SC, 2012.  
 
Adebiyi M.G., Henke K and Harris M.P. Zebrafish as a Model for Craniosynostosis. Poster 
presentation delivered at Leadership Alliance Conference, New Haven, Conn, August, 2011.   
 
Shackleford J, Adebiyi M.G., Akinseye A, Mustafa R and Yerokun T. Characterizing How 
Single Nucleotide Mutations Affect the MSH2 Mismatch Repair Gene and Potential 
Consequence on the Development of Colorectal Cancer. Poster Presentation delivered at 
Spelman College Research Day, Atlanta, GA, 2010.  
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Adebiyi M.G., Dharmasiri U, Njoroge S.K., Witek M, Hupert M and Soper S.A. High-
Throughput Selection, Enumeration, Electrokinetic Manipulation, and Molecular Profiling of 
Low-Abundance Circulating Tumor Cells Using a Microfluidic System. Poster presentation 
delivered at HHMI Undergraduate Summer Research Symposium, Baton Rouge, LA, 2010.  
 
 
PUBLIC SERVICE 
2014 to 2018 Graduate School Biomedical Science 1st Generation Student Group at 
UTHealth/MD Anderson, Voting Member  
2013 to 2018              Association of Minority of Biomedical Researchers, Member 
2017       Graduate Student Biomedical Science Ambassador 
2016 to 2017              Graduate Program of Biochemistry and Molecular Biology Steering 
                                   Committee 
2016 to 2017              Graduate Program of Biochemistry and Molecular Biology Education  
                                   Committee 
2016 to 2017    Biochemistry and Molecular Biology Student Association, President  
2015 to 2016  Biochemistry and Molecular Biology Student Association,  
Vice President  
 
 
MEMBERSHIPS 
 
Association of Minority Biomedical Researchers, Association of First Generation Students, 
the Nigerian-American Multicultural Council, Honor Society for Graduate Students, Beta 
Kappa Chi Scientific Honor Society, National Society of Leadership Success 
 
 
SKILLSETS 
 
Volunteerism: GSBS Science Night  
 
Course work: Scientific Writing, Life Science entrepreneurship, and Network Leadership  
 
 
CONTACT PERSONS  
 Ph.D advisor: Yang Xia, M.D, Ph.D, Professor, McGovern Scholar, Dept. of 
Biochemistry and Molecular Biology, UT Health. Email: yang.xia@uth.tmc.edu, 
Phone: +1 (713) 500-5039   
 Advisory committee member: Rodney E. Kellems, Ph.D, Professor and Chairman, 
Dept. of Biochemistry and Molecular Biology, UT Health. Email: 
rodney.e.kellems@uth.tmc.edu, Phone: +1 (713) 500-6124  Advisory & Candidacy  
 Advisory & Candidacy Examination Committee member:  Dorothy E. Lewis, Ph.D, 
Professor, Dept. of Internal Medicine, UT Health. Email: 
dorothy.e.lewis@uth.tmc.edu, Phone: +1 (713) 500-6809    
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VII. Vita 
 
Morayo Gloria Adebiyi is the daughter of David Adebiyi Sr. and Caroline Aboderin.  Her 
hometown is Atlanta, GA. She is an alumnae of the prestigious Spelman College where she 
majored in Environmental Sciences and Studies. While at Spleman, she volunteered at 
Grady Memorial Hospital Sickle Cell Unit and was a Siemen’s Science Teacher Scholar. 
Due to her interests in biomedical sciences, she accepted a post-baccalaureate position at 
the University of Chicago where she learned biochemistry and molecular biology. In the 
summer of 2013, she enrolled as a graduate student at the University of Texas MD 
Anderson Cancer Center UT Health Graduate School of Biomedical Sciences.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
